id;outcome_n;outcome;additional_comments;type;co_primary;prioritisation;time_point;death_pct;death_handling;missing_pct;missing_handling;effect_measures;stat
RELAx 2020;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;40,2;Dead = 0 days;0,8;CCA;RoM and MD;GAM with ZOIB distribution
REMAP-CAP (steroid domain) 2020;1;DAWO resp circ sup;NA;days alive...;y;NR;day 21 (assumed alive and without life support after hospital discharge);29,3;Dead = worst value, ordinal;1,3;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (steroid domain) 2020;2;DAWO resp sup;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);29,3;Dead = worst value, ordinal;1,3;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (steroid domain) 2020;3;DAWOCS;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);29,3;Dead = worst value, ordinal;1,3;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (steroid domain) 2020;4;WHO ordinal scale for COVID-19;NA;ordinal/other;n;NR;day 14;NA;Included in scale;1,3;CCA;OR;Bayesian cumulative logistic regression model
APROCCHSS 2018;1;DAWOCS;NA;days alive...;n;NR;day 28;36,3;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;36,3;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;3;Muscular Disability Rating Scale (MDRS);NA;functional/cognitive/neurological;n;Three dichotomizations reported with equal prioritisation;day 28;36,3;Last value before death carried forward;0,1;CCA;RR;Logistic regression and Chi-squared or Fisher
APROCCHSS 2018;4;DAWOCS;NA;days alive...;n;NR;day 90;46,1;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;5;DAWOMV/VFD;NA;days alive...;n;NR;day 90;46,1;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;6;DAAOOICU;NA;days alive...;n;NR;day 28;36,3;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;7;DAAOOICU;NA;days alive...;n;NR;day 90;46,1;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;8;DAAOOH;NA;days alive...;n;NR;day 28;36,3;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
APROCCHSS 2018;9;DAAOOH;NA;days alive...;n;NR;day 90;46,1;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
LeoPARDS 2016;1;DAWOCS;NA;days alive...;n;NR;day 28;32,7;Dead = 0 days;0,2;CCA;MD;Non-parametric and bootstrapping
LeoPARDS 2016;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;32,7;Dead = 0 days;0,2;CCA;MD;Non-parametric and bootstrapping
PREVENT 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;15,6;NA;0,1;CCA;Descriptive only;Descriptive only
PREVENT 2019;2;DAWOCS;NA;days alive...;n;NR;day 28;15,6;NA;0,1;CCA;Descriptive only;Descriptive only
PREVENT 2019;3;DAAOOICU;NA;days alive...;n;NR;day 28;15,6;NA;NA;CCA;Descriptive only;Descriptive only
Arabi 2020;1;DAWO resp sup;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;3;DAWORRT;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;4;DAWOCS;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;5;DAWOECMO;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;6;DAWOLS;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;7;DAAOOICU;NA;days alive...;n;NR;day 28;28,4;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
Arabi 2020;8;Karnofsky performance-status;NA;functional/cognitive/neurological;n;NR;day 90;36,8;Included in scale;1,1;CCA;Descriptive only;Descriptive only
Atan 2018;1;HAWOCS;NA;days alive...;y;NR;day 7;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
STARRT-AKI 2020;1;DAWORRT;NA;days alive...;y;NR;day 90;43,8;Dead = 0 days;0,9;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;3;DAWOCS;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;4;DAAOOICU;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;5;DAAOOH;NA;days alive...;n;NR;day 90;43,8;Dead = 0 days;0,9;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;6;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;day 90;43,8;Survivors only;16,8;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;7;EQ-5D-5L VAS;NA;HRQoL;n;NR;day 90;43,8;Survivors only;18,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
STARRT-AKI 2020;8;Clinical Frailty Scale >4;NA;functional/cognitive/neurological;n;NR;day 90;43,8;Survivors only;11,7;CCA;MD;Linear regression/T-test/ANOVA/LMM
IDEAL-ICU 2018;1;DAWORRT;NA;days alive...;n;NR;day 28;43,6;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
IDEAL-ICU 2018;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;43,6;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
IDEAL-ICU 2018;3;DAWOCS;NA;days alive...;n;NR;day 28;43,6;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
Beitler 2019;1;DAWOMV/VFD;"Quote: ""Each patient was compared with every other patient in the study and assigned a score (tie: 0, win: +1, loss: −1) for each pairwise comparison based on whom fared better. If one patient survived and the other did not, scores of +1 and −1 were assigned, respectively, for that pairwise comparison. If both patients in the pairwise com- parison survived, the assigned score depended on which pa- tient had more days free from mechanical ventilation: the pa- tient with more days off the ventilator received a score of +1, while the patient with fewer days received a score of −1. If both patients survived and had the same number of days off the ventilator, or if both patients died, they both were assigned a score of 0 for that pairwise comparison. For each patient, scores for all pairwise comparisons were summed, resulting in a cumulative score for each patient""";days alive...;y;NR;day 28;31,5;Dead = worst value (tie method);0;CCA;Probabilistic index;Non-parametric and probabilistic index
Beitler 2019;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;31,5;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
Beitler 2019;3;DAWOCS;NA;days alive...;n;NR;day 28;31,5;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
HARP-2 2014;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;24,5;Dead = 0 days;0,2;CCA;MD;Linear regression/T-test/ANOVA/LMM and bootstrapping
PreVent 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;MD;GEE with identity link
PreVent 2019;2;DAAOOICU;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;MD;GEE with identity link
PROPER 2021;1;DAAOOICU;NA;days alive...;n;NR;day 28 censored at hospital discharge;NA;Dead = 0 days;0;CCA;OR;POLR
PROPER 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28 censored at hospital discharge;NA;Dead = 0 days;0;CCA;OR;POLR
TARGET 2018;1;DAAOOICU;NA;days alive...;n;NR;day 28;23;Dead = 0 days;0,5;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;2;DAAOOH;NA;days alive...;n;NR;day 28;23;Dead = 0 days;0,5;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;3;DAWOMV/VFD;NA;days alive...;n;NR;day 28;23;Dead = 0 days;0,5;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;4;DAWOCS;NA;days alive...;n;NR;day 28;23;Dead = 0 days;0,1;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;5;DAWORRT;NA;days alive...;n;NR;day 28;23;Dead = 0 days;1,9;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;6;EQ-5D-5L VAS;NA;HRQoL;n;NR;6 months;28,9;Survivors only;8,6;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;7;EQ-5D-5L index;England value set;HRQoL;n;NR;6 months;28,9;Survivors only;9,2;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;8;EQ-5D-5L index;Canada value set;HRQoL;n;NR;6 months;28,9;Survivors only;9,2;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;9;"EQ-5D-5L components - ""no problems""";NA;HRQoL;n;Equal prioritisation;6 months;28,9;Survivors only;8,6;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;10;Australian Labor Force Survey;"Quote: ""For those categorized as age <65 years and in the labor force""";functional/cognitive/neurological;n;Equal prioritisation;6 months;28,9;Survivors only;NA;CCA;RR and Hodges-Lehmann estimate;GLM/GLMM log-binomial and Hodges-Lehmann estimator
TARGET 2018;11;WHODAS score;"Quote: ""For those categorized as 1) age <65 years and not in the labor force, 2) age >65 years and living at home with essential supports, or 3) age >=65 years and living in a long-term care facility""";functional/cognitive/neurological;n;NR;6 months;28,9;Survivors only;NA;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;12;WHODAS no or mild disability;"Quote: ""For those categorized as 1) age <65 years and not in the labor force, 2) age >65 years and living at home with essential supports, or 3) age >=65 years and living in a long-term care facility""";functional/cognitive/neurological;n;NR;6 months;28,9;Survivors only;NA;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;13;WHODAS disability-free survival (<25%);"Quote: ""For those categorized as 1) age <65 years and not in the labor force, 2) age >65 years and living at home with essential supports, or 3) age >=65 years and living in a long-term care facility""";functional/cognitive/neurological;n;NR;6 months;28,9;Survivors only;NA;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;14;Adelaide Activities Profile;"Quote: ""For those categorized as age >65 years and living independently at baseline""";functional/cognitive/neurological;n;Equal prioritisation;6 months;28,9;Dead = worst value;NA;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;15;EQ-5D-5L VAS;Sensitivity analysis;HRQoL;n;NR;6 months;28,9;Dead = worst value;8,6;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;16;EQ-5D-5L index;Sensitivity analysis, England value set;HRQoL;n;NR;6 months;28,9;Dead = worst value;9,2;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;17;EQ-5D-5L index;Sensitivity analysis, Canada value set;HRQoL;n;NR;6 months;28,9;Dead = worst value;9,2;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;18;"EQ-5D-5L components - ""no problems""";NA;HRQoL;n;Equal prioritisation;6 months;28,9;Dead = worst value;9,2;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;19;Australian Labor Force Survey - returned to work;Sensitivity analysis;functional/cognitive/neurological;n;NR;6 months;28,9;Included in definition;NA;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;20;WHODAS score;"Sensitivity analysis, quote: ""For those categorized as 1) age <65 years and not in the labor force, 2) age >65 years and living at home with essential supports, or 3) age >=65 years and living in a long-term care facility""";functional/cognitive/neurological;n;NR;6 months;28,9;Included in definition;NA;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
TARGET 2018;21;WHODAS no or mild disability;"Sensitivity analysis, quote: ""For those categorized as 1) age <65 years and not in the labor force, 2) age >65 years and living at home with essential supports, or 3) age >=65 years and living in a long-term care facility""";functional/cognitive/neurological;n;NR;6 months;28,9;Included in definition;NA;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;22;WHODAS disability-free survival (<25%);"Sensitivity analysis, quote: ""For those categorized as 1) age <65 years and not in the labor force, 2) age >65 years and living at home with essential supports, or 3) age >=65 years and living in a long-term care facility""";functional/cognitive/neurological;n;NR;6 months;28,9;Included in definition;NA;CCA;RR;GLM/GLMM log-binomial
TARGET 2018;23;Adelaide Activities Profile;"Quote: ""For those categorized as age >65 years and living independently at baseline""";functional/cognitive/neurological;n;Equal prioritisation;6 months;28,9;Included in definition;NA;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
Chlan 2014;1;VAS-A;NA;HRQoL;y;NR;day 30;7,7;Survivors only;35,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
IRIHS 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 60;19,9;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
EOLIA 2018;1;DAWOMV/VFD;NA;days alive...;n;NR;day 60;40,6;Dead = 0 days;0;CCA;Median difference;NA
EOLIA 2018;2;DAWOCS;NA;days alive...;n;NR;day 60;40,6;Dead = 0 days;0;CCA;Median difference;NA
EOLIA 2018;3;DAWORRT;NA;days alive...;n;NR;day 60;40,6;Dead = 0 days;0;CCA;Median difference;NA
EOLIA 2018;4;DAAOOICU;NA;days alive...;n;NR;day 60;40,6;Dead = 0 days;0;CCA;Median difference;NA
EOLIA 2018;5;DAWO sedation;NA;days alive...;n;NR;day 60;40,6;Dead = 0 days;0;CCA;Median difference;NA
LIVE 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30;NA;Actual number of days;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
LIVE 2019;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;21,8;Actual number of days;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
POLAR 2018;1;GOS-E 5-8 (favourable outcome);NA;functional/cognitive/neurological;y;NR;6 months;19,8;Included in scale;6,8;CCA;RD and RR;Chi-squared or Fisher and GLM/GLMM log-binomial
POLAR 2018;2;GOS-E;NA;functional/cognitive/neurological;n;NR;6 months;19,8;Included in scale;6,8;CCA;OR;POLR
RIFTS 2019;1;DAWOCS;NA;days alive...;n;NR;day 30;22;NA;0;CCA;Descriptive plus p-value only;Non-parametric
RIFTS 2019;2;DAWOMV/VFD;NA;days alive...;n;NR;day 30;22;NA;0;CCA;Descriptive plus p-value only;Non-parametric
EUPHRATES 2018;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;36,1;Actual number of days;0,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
EUPHRATES 2018;2;DAWORRT;NA;days alive...;n;NR;day 28;36,1;Actual number of days;0,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
CAPE COVID 2020;1;Clinical status (5 levels);Levels: death, presence in the ICU on mechanical ventilation, high-flow or low-flow oxygen therapy, ICU discharge;ordinal/other;n;NR;day 21;20,8;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
CHARLI 2021;1;SF-36 Physical Function Score;NA;functional/cognitive/neurological;y;NR;day 60;16,4;Survivors only;8;CCA;MD;Linear regression/T-test/ANOVA/LMM
CHARLI 2021;2;Time to ventilator separation;NA;days alive...;n;NR;day 28;15,1;Dead = worst value (time to liberation outcome);0,4;CCA;HR;Time-to-event analysis
CHARLI 2021;3;Time to ICU separation;NA;days alive...;n;NR;day 28;15,1;Dead = worst value (time to liberation outcome);0,4;CCA;HR;Time-to-event analysis
CHARLI 2021;4;DAWOCS;NA;days alive...;n;NR;day 28;15,1;Dead = 0 days;0,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
CHARLI 2021;5;DAWORRT;NA;days alive...;n;NR;day 28;15,1;Dead = 0 days;0,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
CHARLI 2021;6;Location/dead (5 levels);Levels: home, residential low-level care, rehabilitation, transfer to another hospital, hospice, deceased;functional/cognitive/neurological;n;NR;day 60;16,4;Included in scale;4,8;CCA;OR;Logistic regression
CHARLI 2021;7;Alive and at home;NA;functional/cognitive/neurological;n;NR;day 60;16,4;Included in definition;8;CCA;OR;Logistic regression
CHARLI 2021;8;Alive and at home;NA;functional/cognitive/neurological;n;NR;day 180;21,1;Included in definition;2,4;CCA;OR;Logistic regression
CHARLI 2021;9;EQ-5D-3L components;NA;HRQoL;n;NR;day 60;16,4;Survivors only;8;CCA;Descriptive plus p-value only;Chi-squared or Fisher
CHARLI 2021;10;EQ-5D-3L components;NA;HRQoL;n;NR;day 180;21,1;Survivors only;6,3;CCA;Descriptive plus p-value only;Chi-squared or Fisher
CHARLI 2021;11;SF-36 Physical Function Score;NA;functional/cognitive/neurological;n;NR;day 60;16,4;Dead = 0;8;CCA;MD;Linear regression/T-test/ANOVA/LMM
CHARLI 2021;12;SF-36 Physical Function Score;NA;functional/cognitive/neurological;n;NR;day 180;21,1;Survivors only;6,3;CCA;MD;Linear regression/T-test/ANOVA/LMM
CHARLI 2021;13;SF-36 Physical Function Score;NA;functional/cognitive/neurological;n;NR;day 180;21,1;Dead = 0;6,3;CCA;MD;Linear regression/T-test/ANOVA/LMM
CHARLI 2021;14;SF-36 Physical Function Score < 20;NA;functional/cognitive/neurological;n;NR;day 60;16,4;Survivors only;8;CCA;OR;Logistic regression
Fossat 2018;1;Medical Research Council muscle strength;NA;functional/cognitive/neurological;y;NR;day of ICU discharge or the following day;18,3;Dead = 0;3,2;MI;Median difference;Non-parametric and bootstrapping
Fossat 2018;2;ICU mobility scale;NA;functional/cognitive/neurological;n;NR;day of ICU discharge or the following day;18,3;Dead = 0;3,2;MI;Median difference;Non-parametric and bootstrapping
Fossat 2018;3;Katz Index;NA;functional/cognitive/neurological;n;NR;day of ICU discharge or the following day;18,3;Dead = 0;5,8;CCA;Median difference;Non-parametric and bootstrapping
Fossat 2018;4;DAWOMV/VFD;NA;days alive...;n;NR;day 28;18,6;NA;NA;CCA;Median difference;Non-parametric
Fossat 2018;5;SF-36;NA;HRQoL;n;Equal prioritisation;6 months;30,1;NA;NA;CCA;Median difference;Non-parametric
Fossat 2018;6;Barthel Index;NA;functional/cognitive/neurological;n;NR;6 months;30,1;NA;NA;CCA;Median difference;Non-parametric
CITRIS-ALI 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;38;Dead = 0 days;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
CITRIS-ALI 2019;2;DAAOOICU;NA;days alive...;n;NR;day 28;38;Actual number of days;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
CITRIS-ALI 2019;3;DAAOOH;NA;days alive...;n;NR;day 60;NA;Actual number of days;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ANTHARTIC 2019;1;CPC scale;NA;functional/cognitive/neurological;n;NR;day 28;40,9;Included in scale;0,5;CCA;Descriptive only;Descriptive only
ANTHARTIC 2019;2;CPC scale;NA;functional/cognitive/neurological;n;NR;day 90;NA;Included in scale;2,1;CCA;Descriptive only;Descriptive only
ANTHARTIC 2019;3;CPC scale;NA;functional/cognitive/neurological;n;NR;6 months;NA;Included in scale;2,6;CCA;Descriptive only;Descriptive only
ANTHARTIC 2019;4;CPC scale;NA;functional/cognitive/neurological;n;NR;12 months;NA;Included in scale;3,1;CCA;Descriptive only;Descriptive only
ANTHARTIC 2019;5;DAWOMV/VFD;NA;days alive...;n;NR;day 28;40,9;Dead = 0 days;0,5;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
Francois 2020;1;DAWOCS;NA;days alive...;n;NR;day 28;18,4;Actual number of days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;18,4;Actual number of days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;3;DAWORRT;NA;days alive...;n;NR;day 28;18,4;Actual number of days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;4;DAWOCS;Sensitivity analysis;days alive...;n;NR;day 28;18,4;Dead = 0 days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;5;DAWOMV/VFD;Sensitivity analysis;days alive...;n;NR;day 28;18,4;Dead = 0 days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;6;DAWORRT;Sensitivity analysis;days alive...;n;NR;day 28;18,4;Dead = 0 days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;7;Location/support/dead (7 levels);"Levels: home receiving no support, home receiving paid professional support, home receiving unpaid support, rehabilitation site / skilled (or unskilled), nursing facility, still in trial hospital, death
";functional/cognitive/neurological;n;Equal prioritisation;day 90;7,7;Included in scale;20,4;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Francois 2020;8;DAWOMV/VFD;NA;days alive...;n;NR;day 25;NA;Dead = 0 days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;9;DAWORRT;NA;days alive...;n;NR;day 25;NA;Dead = 0 days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
Francois 2020;10;DAWOCS;NA;days alive...;n;NR;day 25;NA;Dead = 0 days;NA;LVCF;MD;Linear regression/T-test/ANOVA/LMM
VITAMINS 2020;1;HAWOCS;NA;days alive...;y;NR;day 7 censored after patient has been off pressors for 4 hours;15,2;Dead = 0 hours, but only if on pressors at the time of dead;0;CCA;Hodges-Lehmann estimate and median difference;Hodges-Lehmann estimator and non-parametric and quantile regression
VITAMINS 2020;2;DAWOCS;NA;days alive...;n;NR;day 28;21,5;Actual number of days;0,9;CCA;Median difference;Quantile regression
VITAMINS 2020;3;DAWOMV/VFD;NA;days alive...;n;NR;day 28;21,5;Actual number of days;0,9;CCA;Median difference;Quantile regression
VITAMINS 2020;4;DAWORRT;NA;days alive...;n;NR;day 28;21,5;Actual number of days;1,4;CCA;Median difference;Quantile regression
VITAMINS 2020;5;DAAOOICU;NA;days alive...;n;NR;day 28;21,5;Actual number of days;0,9;CCA;Median difference;Quantile regression
Garrouste-Orgeas 2019;1;PTSD - IES-R score >22;NA;HRQoL;y;NR;3 months after ICU discharge;38,8;Survivors only;9,6;CCA;RD;Chi-squared or Fisher and binomial proportion test/exact binomial CI and logistic regression
Garrouste-Orgeas 2019;2;PTSD - IES-R score;NA;HRQoL;y;NR;3 months after ICU discharge;38,8;Survivors only;9,6;CCA;MD;Non-parametric
Garrouste-Orgeas 2019;3;PTSD - IES domains;NA;HRQoL;y;Equal prioritisation;3 months after ICU discharge;38,8;Survivors only;9,6;CCA;MD;Non-parametric
Garrouste-Orgeas 2019;4;HADS total;NA;HRQoL;n;NR;3 months after ICU discharge;38,8;Survivors only;10;CCA;MD;Non-parametric
Garrouste-Orgeas 2019;5;HADS domains;NA;HRQoL;n;Equal prioritisation;3 months after ICU discharge;38,8;Survivors only;10;CCA;MD;Non-parametric
Garrouste-Orgeas 2019;6;HADS domains;NA;HRQoL;n;Equal prioritisation;3 months after ICU discharge;38,8;Survivors only;10;CCA;RD;Chi-squared or Fisher and binomial proportion test/exact binomial CI and logistic regression
Garrouste-Orgeas 2019;7;ICU memory tool - components yes/no to each;NA;ordinal/other;n;Equal prioritisation;3 months after ICU discharge;38,8;Survivors only;12,6;CCA;RD;Chi-squared or Fisher and binomial proportion test/exact binomial CI and logistic regression
Garrouste-Orgeas 2019;8;ICU memory tool - number of memories;NA;ordinal/other;n;Equal prioritisation;3 months after ICU discharge;38,8;Survivors only;10;CCA;MD;Non-parametric
AKIKI 2 2021;1;DAWORRT;NA;days alive...;y;NR;day 28;41,4;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;41,4;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2 2021;3;DAWOCS;NA;days alive...;n;NR;day 28;41,4;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2 2021;4;Dialysis catheter-free days;NA;days alive...;n;NR;day 28;41,4;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2 2021;5;Barthel Index;NA;functional/cognitive/neurological;n;NR;day 60;49,3;NA;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2016;1;DAWORRT;NA;days alive...;n;NR;day 28;42,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2016;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;42,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2016;3;DAWOCS;NA;days alive...;n;NR;day 28;42,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AKIKI 2016;4;Dialysis catheter-free days;NA;days alive...;n;NR;day 28;42,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
VIOLET 2019;1;Alive and at home;"At home defined as ""previous level of care""";functional/cognitive/neurological;n;NR;day 90;22,1;Included in definition;1,8;CCA;RD;NA
VIOLET 2019;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;15,2;Dead = 0 days;1,8;CCA;MD;NA
VIOLET 2019;3;EQ-5D-5L change from baseline;NA;HRQoL;n;NR;day 90;22,1;NA;1,8;Survivor average causal effects methods;MD;NA
VIOLET 2019;4;RBANS total;NA;functional/cognitive/neurological;n;NR;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;Model-based single imputation;OR;POLR
VIOLET 2019;5;RBANS domains;NA;functional/cognitive/neurological;n;Equal prioritisation;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;Model-based single imputation;OR;POLR
VIOLET 2019;6;D-KEFS total;NA;functional/cognitive/neurological;n;NR;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;Model-based single imputation;OR;POLR
VIOLET 2019;7;D-KEFS domains;NA;functional/cognitive/neurological;n;Equal prioritisation;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;Model-based single imputation;OR;POLR
VIOLET 2019;8;Katz Index;NA;functional/cognitive/neurological;n;NR;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;LVCF;OR;POLR
VIOLET 2019;9;Lawton IADL;NA;functional/cognitive/neurological;n;NR;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;LVCF;OR;POLR
VIOLET 2019;10;Loss of employment (for patients who were fully or partially employed);NA;functional/cognitive/neurological;n;NR;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;LVCF;Descriptive only;Descriptive only
VIOLET 2019;11;Skilled nursing home facility residence;NA;functional/cognitive/neurological;n;NR;12 +/- 4 months (>16 months in some patients);43,4;Survivors only;49,8;LVCF;Descriptive only;Descriptive only
MIND-USA 2018;1;DAWO delirium/coma;NA;days alive...;y;NR;day 14;NA;Actual number of days;NA;Imputation - details unclear;OR;Non-parametric and POLR
Gobatto 2019;1;GOS;NA;functional/cognitive/neurological;n;NR;hospital discharge;18,2;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Gobatto 2019;2;GOS 4-5 (favourable neurologic outcome);NA;functional/cognitive/neurological;n;NR;hospital discharge;18,2;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Gobatto 2019;3;GOS;NA;functional/cognitive/neurological;n;NR;6 months after hospital discharge;20,5;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Gobatto 2019;4;GOS 4-5 (favourable neurologic outcome);NA;functional/cognitive/neurological;n;NR;6 months after hospital discharge;20,5;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
REMAP-CAP (IL-6 domain) 2021;1;DAWO resp circ sup;NA;days alive...;y;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;1,4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (IL-6 domain) 2021;2;DAWO resp sup;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;1,4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (IL-6 domain) 2021;3;DAWOCS;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;1,4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (IL-6 domain) 2021;4;WHO ordinal scale for COVID-19;NA;ordinal/other;n;NR;day 14;NA;Included in scale;2,4;CCA;OR;Bayesian cumulative logistic regression model
HENIVOT 2021;1;DAWO resp sup;NA;days alive...;y;NR;day 28;16,5;NA;0;CCA;MD;Non-parametric
HENIVOT 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;16,5;NA;0;CCA;MD;Non-parametric
HENIVOT 2021;3;DAWOMV/VFD;NA;days alive...;n;NR;day 60;22,9;NA;0;CCA;MD;Non-parametric
Hadfield 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;24,7;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
Hadfield 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 90;34,7;Dead = 0 days;0;CCA;MD;Non-parametric
VANCS II 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;54,8;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
VANCS II 2019;2;DAWOCS;NA;days alive...;n;NR;day 28;54,8;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
VANCS II 2019;3;DAWORRT;NA;days alive...;n;NR;day 28;54,8;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
Hassan 2018;1;DAWOMV/VFD;NA;days alive...;n;NR;NA;24,1;NA;0;CCA;Descriptive plus p-value only;Non-parametric
VAPrapid2 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;23;Actual number of days;0;CCA;RR;Poisson/negative binomial regression
ANDROMEDA SHOCK 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;39,2;Dead = 0 days;0;CCA;RD;ZOIB regression
ANDROMEDA SHOCK 2019;2;DAWORRT;NA;days alive...;n;NR;day 28;39,2;Dead = 0 days;0;CCA;RD;ZOIB regression
ANDROMEDA SHOCK 2019;3;DAWOCS;NA;days alive...;n;NR;day 28;39,2;Dead = 0 days;0;CCA;RD;ZOIB regression
PROPEL 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;NA
PROMOTE 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30;28,3;Actual number of days;0;CCA;Descriptive only;Descriptive only
ARISE 2014;1;EQ-5D-3L VAS;NA;HRQoL;n;NR;6 months;22,2;Survivors only;14,7;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;2;EQ-5D-3L VAS;NA;HRQoL;n;NR;12 months;27,1;Survivors only;12;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;3;EQ-5D-3L index;United Kingdom value set;HRQoL;n;NR;6 months;22,2;Survivors only;12,3;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;4;EQ-5D-3L index;United Kingdom value set;HRQoL;n;NR;12 months;27,1;Survivors only;10,8;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;5;SF-36;NA;HRQoL;n;Equal prioritisation;6 months;22,2;Survivors only;48,2;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;6;SF-36;NA;HRQoL;n;Equal prioritisation;12 months;27,1;Survivors only;44,1;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;9;Assessment of Quality of Life 4D utility score;NA;HRQoL;n;NR;6 months;22,2;Survivors only;45,3;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;10;Assessment of Quality of Life 4D utility score;NA;HRQoL;n;NR;12 months;27,1;Survivors only;40,7;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ARISE 2014;11;Discharge destination (4 levels);Levels: home, rehabilitation, long-term care facility, other hospital;functional/cognitive/neurological;n;NR;hospital discharge;15,1;Survivors only;0,3;CCA;RD;Chi-squared or Fisher
Hirshberg 2018;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
PHARLAP 2019;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;25,7;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
MENDS2 2021;1;DAWO delirium/coma;NA;days alive...;y;NR;day 14;NA;Actual number of days;0;CCA;OR;POLR
MENDS2 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Actual number of days, except days not counted if dead within 48 h after extubation OR intubated again;0,2;CCA;OR;POLR
MENDS2 2021;3;TICS-T total score (age adjusted);NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;OR;POLR
MENDS2 2021;4;Katz Index;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;5;Pfeffer FAQ (performance score);NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;6;EQ-5D index (unclear if 3L or 5L);NA;HRQoL;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;7;Memory score - Digit Span score;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;8;Logical Memory I score;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;9;Logical Memory II score;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;10;Logic thinking - Similarities score;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;11;Verbal fluency - Controlled Oral Word Association T-score;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;12;Hayling Sentence completion score;NA;functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;Descriptive only;Descriptive only
MENDS2 2021;13;Presence of cognitive impairment based on multiple tests;"Quote: ""A patient was defined as being cognitively impaired if they were ≥2 standard deviations below the population adjusted mean in 1 test or ≥1.5 standard deviations below the population adjusted mean in any two tests, where the tests consisted of the Digit Span, Logical Memory I, Logical Memory II, Similarities, Controlled Oral Word Association, and Hayling Sentence Completion.""";functional/cognitive/neurological;n;NR;6 months;45,6;Survivors only;5;CCA;HR;Time-to-event analysis
MENDS2 2021;14;Composite, days between randomisation and death and age-adjusted TICS-T score;"Quote: ""A sensitivity analysis was conducted using a composite end point of the days between randomization and death (if applicable) plus the continuous ageadjusted TICS-T score (if assessed). For example, the outcome was the days between randomization and death (for patients that died prior to assessment) or the days between randomization and date of last follow-up (for patients who were lost to follow up). If the patient survived and was successfully assessed with the TICS, then the outcome was defined to be the days between randomization and planned assessment (180 days) plus the age-adjusted TICS-T assessment score. If the patient survived but had missing TICS-T score at 6 months, then the outcome was defined to be 180 days.""";functional/cognitive/neurological;n;NR;6 months;45,6;Included in definition;5;CCA;Descriptive only;Descriptive only
ATESS 2020;1;DAWOCS;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
ATESS 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
ATESS 2020;3;DAWORRT;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
ATESS 2020;4;DAAOOICU;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
ORANGES 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Actual number of days;NA;CCA;Descriptive plus p-value only;Non-parametric
TRANSFUSE 2017;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;19,1;NA;0,7;CCA;Descriptive plus p-value only;Non-parametric
TRANSFUSE 2017;2;DAWORRT;NA;days alive...;n;NR;day 28;19,1;NA;0,7;CCA;Descriptive plus p-value only;Non-parametric
TRANSFUSE 2017;3;EQ-5D-3L index;United Kingdom value set;HRQoL;n;NR;day 180;28,3;Dead = 0;8,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
TRANSFUSE 2017;4;EQ-5D-3L index;United Kingdom value set;HRQoL;n;NR;day 180;28,3;Survivors only;8,4;CCA;MD;Linear regression/T-test/ANOVA/LMM
TRANSFUSE 2017;5;EQ-5D-3L components;NA;HRQoL;n;Equal prioritisation;day 180;28,3;Survivors only;8,4;CCA;RD;Chi-squared or Fisher
CASS 2018;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30;40;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
CASS 2018;2;DAWOCS;NA;days alive...;n;NR;day 30;40;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
CASS 2018;3;DAWORRT;NA;days alive...;n;NR;day 30;40;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
BICAR-ICU 2018;1;DAWORRT;NA;days alive...;n;NR;day 28 (but only in-ICU);49,1;Actual number of days;0;CCA;NA;NA
BICAR-ICU 2018;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28 (but only in-ICU);49,1;Actual number of days;0;CCA;NA;NA
BICAR-ICU 2018;3;DAWOCS;NA;days alive...;n;NR;day 28 (but only in-ICU);49,1;Actual number of days;0;CCA;NA;NA
BICAR-ICU 2018;4;DAAOOICU;NA;days alive...;n;NR;day 28 (but only in-ICU);49,1;Actual number of days;0;CCA;NA;NA
STYLETO 2021;1;DAAOOICU;NA;days alive...;n;NR;day 28;30,8;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
STYLETO 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;30,8;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
Jaiswal 2019;1;DAWO delirium/coma;NA;days alive...;n;NR;8 days (within ICU);NA;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
Jaiswal 2019;2;DAWO coma;NA;days alive...;n;NR;8 days (within ICU);NA;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
Jaiswal 2019;3;DAWOMV/VFD;NA;days alive...;n;NR;NA;NA;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
COMACARE 2018;1;CPC scale 1-2 (alive with good neurological outcome);NA;functional/cognitive/neurological;n;NR;6 months;63,3;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
PrePARE 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28 censored at hospital discharge;31,7;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
PrePARE 2019;2;DAAOOICU;NA;days alive...;n;NR;day 28 censored at hospital discharge;31,7;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
Check-UP 2018;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
Check-UP 2018;2;DAAOOICU;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
Kacmarek 2020;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;NA;Dead = 0 days;0;CCA;Median difference;Non-parametric and bootstrapping
J-LAND 3S 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;16;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
J-LAND 3S 2020;2;DAAOOICU;NA;days alive...;n;NR;day 28;16;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
J-LAND 3S 2020;3;DAAOOH;NA;days alive...;n;NR;day 28;16;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
SUP-ICU 2018;1;DAWOLS;NA;days alive...;n;NR;day 90;30,7;Percentage of days out of the total number of days alive (not counting days where the patient was dead in either numerator or denominator);0,3;CCA;Descriptive plus p-value only;Non-parametric
Kredentser 2018;1;ICU memory tool;NA;ordinal/other;n;Equal prioritisation;1 week post ICU discharge;NA;Survivors only;NA;CCA;Descriptive for the entire trial only;Descriptive for the entire trial only
Kredentser 2018;2;HADS domains;NA;HRQoL;n;Equal prioritisation;30 days post ICU discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Kredentser 2018;3;HADS domains;NA;HRQoL;n;Equal prioritisation;90 days post ICU discharge;24;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Kredentser 2018;4;PTSD - IES-R score;NA;HRQoL;n;NR;30 days post ICU discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Kredentser 2018;5;PTSD - IES-R score;NA;HRQoL;n;NR;90 days post ICU discharge;24;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Kredentser 2018;6;HADS domains;NA;HRQoL;n;Equal prioritisation;30 days post ICU discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Kredentser 2018;7;HADS domains;NA;HRQoL;n;Equal prioritisation;90 days post ICU discharge;24;Survivors only;NA;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Kredentser 2018;8;PTSD - IES-R score, mean item score >= 1.6;NA;HRQoL;n;NR;30 days post ICU discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Kredentser 2018;9;PTSD - IES-R score, mean item score >= 1.6;NA;HRQoL;n;NR;90 days post ICU discharge;24;Survivors only;NA;CCA;Descriptive plus p-value only;Chi-squared or Fisher
65 trial 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;36,8;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
65 trial 2020;2;DAWORRT;NA;days alive...;n;NR;day 28;36,8;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
65 trial 2020;3;IQCODE short version (cognitive decline);NA;functional/cognitive/neurological;n;NR;day 90;42,4;Survivors only;18,6;MI;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
65 trial 2020;4;IQCODE short version (cognitive decline);NA;functional/cognitive/neurological;n;NR;1 year;NA;Survivors only;15,1;MI;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
65 trial 2020;5;EQ-5D-5L index;NA;HRQoL;n;NR (individual categories/domains secondarily reported but not analysed);day 90;42,4;Survivors only;18;MI;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
65 trial 2020;6;EQ-5D-5L index;NA;HRQoL;n;NR (individual categories/domains secondarily reported but not analysed);1 year;NA;Survivors only;15,4;MI;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
HYPERION 2019;1;CPC scale 1-2 (alive with good neurological outcome);NA;functional/cognitive/neurological;y;NR (individual categories/domains secondarily reported but not analysed);day 90;82,3;Included in scale;0,5;CCA;RD;Linear regression/T-test/ANOVA/LMM and non-parametric
ORI2 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;Descriptive plus p-value only;Non-parametric
SEPSIS-ACT 2019;1;DAWO resp circ sup;NA;days alive...;y;NR;day 30;34,8;Dead = 0 days;0;CCA;MD;Non-parametric
SEPSIS-ACT 2019;2;DAWORRT;NA;days alive...;n;NR;day 30;34,8;Dead = 0 days;0;CCA;MD;Non-parametric
SEPSIS-ACT 2019;3;DAAOOICU;NA;days alive...;n;NR;day 30;34,8;Dead = 0 days;0;CCA;MD;Non-parametric
SEPSIS-ACT 2019;4;DAWOCS;NA;days alive...;n;NR;day 30;34,8;Dead = 0 days;0;CCA;MD;Non-parametric
SEPSIS-ACT 2019;5;DAWOMV/VFD;NA;days alive...;n;NR;day 30;34,8;Dead = 0 days;0;CCA;MD;Non-parametric
SEPSIS-ACT 2019;6;DAAOOH;NA;days alive...;n;NR;day 90;41,5;Dead = 0 days;0;CCA;MD;Non-parametric
SEPSIS-ACT 2019;7;EQ-5D-5L VAS;NA;HRQoL;n;NR;6 months;44,3;Survivors only;10;CCA;MD;Non-parametric
SEPSIS-ACT 2019;8;EQ-5D-5L index;NA;HRQoL;n;NR;6 months;44,3;Survivors only;9,3;CCA;MD;Non-parametric
Li 2020;1;Time to clinical improvement (6 level ordinal scale);Levels: death, hospitalization plus extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation, supplemental oxygen, hospitalization plus supplemental oxygen (not high-flow or noninvasive ventilation), hospitalization with no supplemental oxygen, hospital discharge;ordinal/other;y;NR;day 28;19,8;Included in scale;0;CCA;HR;Time-to-event analysis
Li 2020;2;Clinical improvement (6-level ordinal scale);Levels: death, hospitalization plus extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation, supplemental oxygen, hospitalization plus supplemental oxygen (not high-flow or noninvasive ventilation), hospitalization with no supplemental oxygen, hospital discharge;ordinal/other;n;NR;day 7;NA;Included in scale;0;CCA;OR;Chi-squared or Fisher
Li 2020;3;Clinical improvement (6-level ordinal scale);Levels: death, hospitalization plus extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation, supplemental oxygen, hospitalization plus supplemental oxygen (not high-flow or noninvasive ventilation), hospitalization with no supplemental oxygen, hospital discharge;ordinal/other;n;NR;day 14;NA;Included in scale;0;CCA;OR;Chi-squared or Fisher
Li 2020;4;Clinical improvement (6-level ordinal scale);Levels: death, hospitalization plus extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation, supplemental oxygen, hospitalization plus supplemental oxygen (not high-flow or noninvasive ventilation), hospitalization with no supplemental oxygen, hospital discharge;ordinal/other;n;NR;day 28;19,8;Included in scale;0;CCA;OR;Chi-squared or Fisher
ROCIT 2021;1;DAAOOH;"Quote: ""Days spent in a rehabilitation facility or high-level nursing facility to Day 60 were considered as days in hospital""";days alive...;y;NR;day 60;15;Dead = 0 days;0;CCA;Median difference;Non-parametric and quantile regression
ROCIT 2021;2;EQ-5D-5L index;Australian value set;HRQoL;n;NR;day 60;15;Dead = 0;0;CCA;Median difference;Non-parametric and quantile regression
ROCIT 2021;3;EQ-5D-5L VAS;NA;HRQoL;n;NR;day 60;15;Survivors only;0;CCA;Median difference;Non-parametric and quantile regression
ROCIT 2021;4;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;day 60;15;Survivors only;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Liu 2018;1;DAWOCS;NA;days alive...;n;NR;day 28;39;NA;0,8;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM and non-parametric
FROST-I 2018;1;modified Rankin Scale score <= 3 (alive with good neurological outcome);NA;functional/cognitive/neurological;y;NR;day 90;28,7;Included in scale;0;CCA;HR;Chi-squared or Fisher and time-to-event analysis
FROST-I 2018;2;modified Rankin Scale score <= 2 (alive with good neurological outcome);NA;functional/cognitive/neurological;n;NR;day 90;28,7;Included in scale;0;CCA;HR;Chi-squared or Fisher and time-to-event analysis
FROST-I 2018;3;CPC scale 1-2 (alive with good neurological outcome);NA;functional/cognitive/neurological;n;NR;day 90;28,7;Included in scale;0;CCA;Descriptive plus p-value only;Time-to-event analysis
ICU-ROX 2020;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;NA;Dead = 0 days;0;CCA;Median difference and MD;Non-parametric and quantile regression and linear regression/T-test/ANOVA/LMM
ICU-ROX 2020;2;DAWOCS;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;Median difference and MD;Quantile regression and linear regression/T-test/ANOVA/LMM
ICU-ROX 2020;3;Proportion of patients in paid employment at baseline who were unemployed at day 180;NA;functional/cognitive/neurological;n;NR;day 180;35,1;Survivors only;NA;CCA;Descriptive plus p-value only;Chi-squared or Fisher
ICU-ROX 2020;4;TICS;NA;functional/cognitive/neurological;n;NR;day 180;35,1;Survivors only;23;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ICU-ROX 2020;5;TICS categorised;NA;functional/cognitive/neurological;n;Equal prioritisation;day 180;35,1;Survivors only;23;CCA;Descriptive plus p-value only;Chi-squared or Fisher
ICU-ROX 2020;6;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;day 180;35,1;Survivors only;13,8;CCA;Descriptive plus p-value only;Chi-squared or Fisher
ICU-ROX 2020;7;EQ-5D-5L VAS;NA;HRQoL;n;NR;day 180;35,1;Survivors only;13,7;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ICU-ROX 2020;8;GOS-E 1-4 (death or unfavourable neurological outcome);NA;functional/cognitive/neurological;n;NR;day 180;50,6;Included in definition;9,6;CCA;OR;Logistic regression and Chi-squared or Fisher
AGATE 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;21,7;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
AGATE 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 60;23,3;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
VITdAL-ICU 2014;1;SF-12;NA;HRQoL;n;Equal prioritisation;6 months;38,9;Survivors only;0,2;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
VITdAL-ICU 2014;2;ECOG performance status;NA;functional/cognitive/neurological;n;NR;6 months;38,9;Survivors only;0,2;CCA;Descriptive plus p-value only;Chi-squared or Fisher
VITdAL-ICU 2014;3;Hand grip strength;NA;functional/cognitive/neurological;n;NR;6 months;38,9;Survivors only;45,1;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
VITdAL-ICU 2014;4;Timed up and go test;NA;functional/cognitive/neurological;n;NR;6 months;38,9;Survivors only;45,3;CCA;Descriptive plus p-value only;Non-parametric
ProCESS 2014;1;Discharge destination (6 levels);Levels: not discharged, discharged to a long-term acute care facility, discharged to another acute care hospital, dischargd to nursing home, discharged home, other or unknown;functional/cognitive/neurological;n;NR;day 60;19,3;Survivors only;NA;"Categorized as ""other or unknown"" with other values";Descriptive plus p-value only;Chi-squared or Fisher
START 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;25;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
START 2019;2;DAAOOICU;NA;days alive...;n;NR;day 28;25;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
START 2019;3;DAWOMV/VFD;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
START 2019;4;DAAOOICU;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
START 2019;5;DAWOCS;NA;days alive...;n;NR;day 14;NA;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
PROTECTION 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;18,6;NA;0;CCA;Descriptive plus p-value only;Non-parametric
LaSRS 2006;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
LaSRS 2006;2;DAAOOICU;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
LaSRS 2006;3;DAWOMV/VFD;NA;days alive...;n;NR;day 180;31,7;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
LaSRS 2006;4;DAAOOICU;NA;days alive...;n;NR;day 180;31,7;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
SedaEN 2019;1;DAWO coma;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
SedaEN 2019;2;DAWO delirium;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
SedaEN 2019;3;DAWO delirium/coma;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
SedaEN 2019;4;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
ACTS 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 7;NA;If dead while on life support = 0 days, otherwise actual number of days;NA;CCA;Median difference;Quantile regression
ACTS 2020;2;DAWOCS;NA;days alive...;n;NR;day 7;NA;If dead while on life support = 0 days, otherwise actual number of days;NA;CCA;Median difference;Quantile regression
ACTS 2020;3;DAAOOICU;NA;days alive...;n;NR;day 28;NA;Actual number of days;NA;CCA;Median difference;Quantile regression
ROSE 2019;1;DAAOOICU;NA;days alive...;n;NR;day 28;36,9;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;36,9;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;3;DAAOOH;NA;days alive...;n;NR;day 28;36,9;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;4;modified Brice questionnaire;NA;ordinal/other;n;NR;in-hospital;36,9;Dead included in analysis without having had the event;0;CCA;RD;Chi-squared or Fisher
ROSE 2019;5;Medical Research Council muscle strength;NA;functional/cognitive/neurological;n;NR;day 7;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;6;Medical Research Council muscle strength;NA;functional/cognitive/neurological;n;NR;day 28;36,9;Survivors only;53,6;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;7;Medical Research Council muscle strength <48 (ICU-acquired weakness);NA;functional/cognitive/neurological;n;NR;day 7;NA;Survivors only;53,6;CCA;RD;Chi-squared or Fisher
ROSE 2019;8;Medical Research Council muscle strength <48 (ICU-acquired weakness);NA;functional/cognitive/neurological;n;NR;day 28;36,9;Survivors only;53,4;CCA;RD;Chi-squared or Fisher
ROSE 2019;9;EQ-5D-5L index;NA;HRQoL;n;NR;3 months;42,6;Survivors only;17,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;10;Difficulty in a daily activity;Difficulty in any domain in Katz Index, Lawton Instrumental Activities of Daily Living, or Nagi scale items;functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;16,8;CCA;RD;Chi-squared or Fisher
ROSE 2019;11;Disability score;"0 to 10; the number of those 10 ADL/IADL/Nagi items on which the respondent or their proxy reported difficulty due to health conditions";functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;16,8;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;12;Self-rated health (5 levels);"Quote: ""five-point categorical score with 1 indicating excellent health and 5 indicating poor health""";HRQoL;n;NR;3 months;42,6;Survivors only;25,3;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;13;Pain interference (5 levels);"Quote: ""five-point categorical score with 1 indicating excellent health and 5 indicating poor health""";HRQoL;n;NR;3 months;42,6;Survivors only;25,6;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;14;MoCA Blind;NA;functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;28,8;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;15;AD8 (cognition);NA;functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;16;Location of residence, % home;NA;functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;16,9;CCA;RD;Chi-squared or Fisher
ROSE 2019;17;Return to work;NA;functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;16,8;CCA;RD;Chi-squared or Fisher
ROSE 2019;18;Significant change in work duties;NA;functional/cognitive/neurological;n;NR;3 months;42,6;Survivors only;34,9;CCA;RD;Chi-squared or Fisher
ROSE 2019;19;Impact on daily activities (any of 10 items);Items: eating, getting in or out of bed, using the toilet, preparing a hot meal, making phone calls, taking medications, managing money, shopping for groceries, stooping kneeling or crouhching, lifting/carrying weights >10 punds;functional/cognitive/neurological;n;Equal prioritisation;3 months;42,6;Survivors only;9,2;CCA;RD;Chi-squared or Fisher
ROSE 2019;20;EQ-5D-5L index;NA;HRQoL;n;NR;6 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;21;Difficulty in a daily activity;Difficulty in any domain in Katz Index, Lawton Instrumental Activities of Daily Living, or Nagi scale items;functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;22;Disability score;"0 to 10; the number of those 10 ADL/IADL/Nagi items on which the respondent or their proxy reported difficulty due to health conditions";functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;23;Self-rated health (5 levels);"Quote: ""five-point categorical score with 1 indicating excellent health and 5 indicating poor health""";HRQoL;n;NR;6 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;24;Pain interference (5 levels);"Quote: ""five-point categorical score with 1 indicating excellent health and 5 indicating poor health""";HRQoL;n;NR;6 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;25;PTSS >45 (post-traumatic stress-like symptoms);NA;HRQoL;n;NR;6 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;26;MoCA Blind;NA;functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;27;AD8 (cognition);NA;functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;28;Location of residence, % home;NA;functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;29;Return to work;NA;functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;30;Significant change in work duties;NA;functional/cognitive/neurological;n;NR;6 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;31;Impact on daily activities (any of 10 items);Items: eating, getting in or out of bed, using the toilet, preparing a hot meal, making phone calls, taking medications, managing money, shopping for groceries, stooping kneeling or crouhching, lifting/carrying weights >10 punds;functional/cognitive/neurological;n;Equal prioritisation;6 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;32;EQ-5D-5L index;NA;HRQoL;n;NR;12 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;33;Difficulty in a daily activity;Difficulty in any domain in Katz Index, Lawton Instrumental Activities of Daily Living, or Nagi scale items;functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;34;Disability score;"0 to 10; the number of those 10 ADL/IADL/Nagi items on which the respondent or their proxy reported difficulty due to health conditions";functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;35;Self-rated health (5 levels);"Quote: ""five-point categorical score with 1 indicating excellent health and 5 indicating poor health""";HRQoL;n;NR;12 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;36;Pain interference (5 levels);"Quote: ""five-point categorical score with 1 indicating excellent health and 5 indicating poor health""";HRQoL;n;NR;12 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;37;PTSS >45 (post-traumatic stress-like symptoms);NA;HRQoL;n;NR;12 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;38;MoCA Blind;NA;functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;39;AD8 (cognition);NA;functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ROSE 2019;40;Location of residence, % home;NA;functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;41;Return to work;NA;functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;42;Significant change in work duties;NA;functional/cognitive/neurological;n;NR;12 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
ROSE 2019;43;Impact on daily activities (any of 10 items);Items: eating, getting in or out of bed, using the toilet, preparing a hot meal, making phone calls, taking medications, managing money, shopping for groceries, stooping kneeling or crouhching, lifting/carrying weights >10 punds;functional/cognitive/neurological;n;Equal prioritisation;12 months;NA;Survivors only;NA;CCA;RD;Chi-squared or Fisher
Nakanishi 2020;1;ICU mobility scale;NA;functional/cognitive/neurological;n;NR;ICU discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Nakanishi 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;NA;NA;CCA;Descriptive plus p-value only;Non-parametric
Nakanishi 2020;3;DAAOOICU;NA;days alive...;n;NR;day 28;NA;NA;NA;CCA;Descriptive plus p-value only;Non-parametric
DESIRE 2017;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;23,4;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
HYPERS2S 2017;1;DAWOCS;NA;days alive...;n;NR;day 28;39,2;Actual number of days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
HYPERS2S 2017;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;39,2;Actual number of days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
HYPERS2S 2017;3;DAWORRT;NA;days alive...;n;NR;day 28;39,2;Actual number of days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
NONSEDA 2020;1;DAWO delirium/coma;NA;days alive...;n;NR;day 28;30,3;NA;0;CCA;Median difference;Non-parametric and bootstrapping
NONSEDA 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;30,3;NA;0;CCA;Median difference;Non-parametric and bootstrapping
NONSEDA 2020;3;DAWOMV/VFD;NA;days alive...;n;NR;day 90;39,7;NA;0;CCA;Median difference;Non-parametric and bootstrapping
NONSEDA 2020;4;Cognitive function on individual level;No, mild-to-moderate, or severe cognitive impairment based on results from multiple cognitive tests;functional/cognitive/neurological;n;NR;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
NONSEDA 2020;5;Span of numbers;NA;functional/cognitive/neurological;n;NR;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Non-parametric
NONSEDA 2020;6;Coding test (translate numbers into figures using an answer key);NA;functional/cognitive/neurological;n;NR;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
NONSEDA 2020;7;Trailmaking A;NA;functional/cognitive/neurological;n;NR;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Non-parametric
NONSEDA 2020;8;Trailmaking B;NA;functional/cognitive/neurological;n;NR;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Non-parametric
NONSEDA 2020;9;Rey auditory verbal learning test, immediate + recall;NA;functional/cognitive/neurological;n;Equal prioritisation;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
NONSEDA 2020;10;Rey-Osterrieth complex figure test (copy);NA;functional/cognitive/neurological;n;NR;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Non-parametric
NONSEDA 2020;11;Rey-Osterrieth complex figure test (immediate recall, delayed recall, recognition);NA;functional/cognitive/neurological;n;Equal prioritisation;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM and non-parametric
NONSEDA 2020;12;Verbal fluency test (S-words and animals);NA;functional/cognitive/neurological;n;Equal prioritisation;3 months after ICU discharge;42,4;Survivors only;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Park 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;49,7;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
Park 2019;2;DAWOCS;NA;days alive...;n;NR;day 28;49,7;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
Fluids After Bypass Study 2021;1;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;hospital discharge;2,7;Survivors only;NA;CCA;Descriptive only;Descriptive only
Fluids After Bypass Study 2021;2;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;3 months;2,5;Survivors only;NA;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Fluids After Bypass Study 2021;3;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;6 months;4,1;Survivors only;NA;CCA;Descriptive only;Descriptive only
Fluids After Bypass Study 2021;4;WHODAS disability-free survival (<25%);NA;functional/cognitive/neurological;n;NR;hospital discharge;2,7;Survivors only;5,6;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Fluids After Bypass Study 2021;5;WHODAS disability-free survival (<25%);NA;functional/cognitive/neurological;n;NR;3 months;2,5;Survivors only;8,7;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Fluids After Bypass Study 2021;6;WHODAS disability-free survival (<25%);NA;functional/cognitive/neurological;n;NR;6 months;4,1;Survivors only;8,7;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Fluids After Bypass Study 2021;7;Discharge destination (5 levels);Levels: other ICU, other acute care hospital, home, rehabilitation hospital, nursing home/long term care;functional/cognitive/neurological;n;NR;ICU discharge;2,7;Survivors only;2,1;CCA;Descriptive only;Descriptive only
Patel 2016;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
Patel 2016;2;Medical Research Council muscle strength <48 (ICU-acquired weakness);NA;functional/cognitive/neurological;n;NR;hospital discharge;41;Included in definition;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Patel 2016;3;Functional independence (patient-reported);"Quote: ""defined as independence in all activities of daily living (ADLs) and independent ambulation as determined by a blinded therapist""";functional/cognitive/neurological;n;NR;hospital discharge;41;Survivors only;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Patel 2016;4;Discharge destination (7 levels);Levels: home, long-term acute care, acute rehabilitation, subacute rehabilitation, skilled nursing facility, hospice, dead;functional/cognitive/neurological;n;NR;hospital discharge;41;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Patel 2016;5;Functional independence (patient-reported);"Quote: ""defined as independence in all activities of daily living (ADLs) and independent ambulation as determined by a blinded therapist""";functional/cognitive/neurological;n;NR;1 year;55,4;Included in definition;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Patel 2016;6;DAAAH;NA;days alive...;n;NR;1 year;55,4;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric
Perkins 2018;1;EQ-5D-3L index change from baseline;NA;HRQoL;n;NR;3 months;23,4;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
Perkins 2018;2;EQ-5D-3L index change from baseline;NA;HRQoL;n;NR;6 months;24,2;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
Perkins 2018;3;EQ-5D-3L VAS;NA;HRQoL;n;NR;3 months;23,4;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
Perkins 2018;4;EQ-5D-3L VAS;NA;HRQoL;n;NR;6 months;24,2;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
Perkins 2018;5;SF-12;NA;HRQoL;n;Equal prioritisation;3 months;23,4;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
Perkins 2018;6;SF-12;NA;HRQoL;n;Equal prioritisation;6 months;24,2;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
STOP-AKI 2018;1;DAWORRT;NA;days alive...;n;NR;day 28;20,3;Actual number of days;NA;Interpolation based on measured values and extrapolation using LVCF;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
STOP-AKI 2018;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;20,3;Actual number of days;NA;Interpolation based on measured values and extrapolation using LVCF;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
STOP-AKI 2018;3;DAWOCS;NA;days alive...;n;NR;day 28;20,3;Actual number of days;NA;Interpolation based on measured values and extrapolation using LVCF;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
STOP-AKI 2018;4;EQ-5D index (unclear if 3L or 5L);NA;HRQoL;n;NR;ICU discharge;NA;NA;NA;Interpolation based on measured values and extrapolation using LVCF;Descriptive only;Descriptive only
STOP-AKI 2018;5;EQ-5D index (unclear if 3L or 5L);NA;HRQoL;n;NR;day 90;23,4;NA;NA;Interpolation based on measured values and extrapolation using LVCF;Descriptive only;Descriptive only
INTEREST 2020;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;24,7;Dead = worst value, ordinal;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
INTEREST 2020;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;24,7;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
INTEREST 2020;3;DAWORRT;NA;days alive...;n;NR;day 28;24,7;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
INTEREST 2020;4;DAWOCS;NA;days alive...;n;NR;day 28;24,7;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
INTEREST 2020;5;DAAOOICU;NA;days alive...;n;NR;day 28;24,7;Dead = 0 days;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
NUTRIREA-2 2018;1;DAWOCS;NA;days alive...;n;NR;day 28;35,9;Actual number of days;0,4;Single imputation - worst case imputation;Descriptive plus p-value only;Non-parametric
NUTRIREA-2 2018;2;DAWORRT;NA;days alive...;n;NR;day 28;35,9;Actual number of days;0,4;Single imputation - worst case imputation;Descriptive plus p-value only;Non-parametric
NUTRIREA-2 2018;3;DAWOMV/VFD;NA;days alive...;n;NR;day 28;35,9;Actual number of days;0,4;Single imputation - worst case imputation;Descriptive plus p-value only;Non-parametric
Ridley 2018;1;ICU mobility scale or 6-minute walk test;NA;functional/cognitive/neurological;n;NR;hospital discharge;27,3;Survivors only;14,1;CCA;Descriptive plus p-value only;Non-parametric
Ridley 2018;2;Hand grip strength;NA;functional/cognitive/neurological;n;NR;hospital discharge;27,3;Survivors only;29,3;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Ridley 2018;3;EQ-5D-3L index;NA;HRQoL;n;NR;hospital discharge;27,3;Survivors only;28,3;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Ridley 2018;4;EQ-5D-3L index;NA;HRQoL;n;NR;day 90;32,3;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Ridley 2018;5;EQ-5D-3L index;NA;HRQoL;n;NR;day 180;32,3;Survivors only;NA;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
COBI 2021;1;GOS-E;NA;functional/cognitive/neurological;y;NR;6 months;18,4;Included in scale;3;MI;OR;POLR
COBI 2021;2;GOS-E 6-8 (good outcome);NA;functional/cognitive/neurological;n;NR;6 months;18,4;Included in scale;3;CCA;RD and OR;Logistic regression
COBI 2021;3;GOS-E 6-8 (good outcome);NA;functional/cognitive/neurological;n;NR;3 months;17,3;Included in scale;5,1;CCA;RD and OR;Logistic regression
COBI 2021;4;Galveston Orientation and Amnesia Test <75/100 (post-traumatic amnesia);NA;functional/cognitive/neurological;n;NR;ICU discharge;3,2;Survivors only;NA;CCA;RD and OR;Logistic regression
COBI 2021;5;Galveston Orientation and Amnesia Test <75/100 (post-traumatic amnesia);NA;functional/cognitive/neurological;n;NR;3 months;17,3;Survivors only;27;CCA;RD and OR;Logistic regression
COBI 2021;6;Galveston Orientation and Amnesia Test <75/100 (post-traumatic amnesia);NA;functional/cognitive/neurological;n;NR;6 months;18,4;Survivors only;21,1;CCA;RD and OR;Logistic regression
COBI 2021;7;Katz Index;NA;functional/cognitive/neurological;n;NR;3 months;17,3;Included in definition;5,7;CCA;RD and OR;Logistic regression
COBI 2021;8;Katz Index;NA;functional/cognitive/neurological;n;NR;6 months;18,4;Included in definition;3,8;CCA;RD and OR;Logistic regression
COBI 2021;9;SF-36;NA;HRQoL;n;Equal prioritisation;3 months;17,3;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
COBI 2021;10;SF-36;NA;HRQoL;n;Equal prioritisation;6 months;18,4;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
COBI 2021;11;Alive and at home;NA;functional/cognitive/neurological;n;NR;3 months;17,3;Included in definition;3;CCA;RD and OR;Logistic regression
COBI 2021;12;Alive and at home;NA;functional/cognitive/neurological;n;NR;6 months;18,4;Included in definition;3;CCA;RD;Logistic regression
ICU Visits 2019;1;DAWOMV/VFD;NA;days alive...;n;NR;day 7;NA;Dead = 0 days;0;CCA;MD;GEE with identity link
ICU Visits 2019;2;DAWO coma;NA;days alive...;n;NR;day 7;NA;Dead = 0 days;0;CCA;MD;GEE with identity link
TTM 2013;1;CPC scale 3-5 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 180;49;Included in scale;0,6;CCA;RR;Non-parametric and logistic regression
TTM 2013;2;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 180;49;Included in scale;0,6;CCA;RR;Non-parametric and logistic regression
TTM 2013;3;CPC scale;NA;functional/cognitive/neurological;n;NR;day 180;49;Included in scale;0,6;CCA;Descriptive plus p-value only;Chi-squared or Fisher
TTM 2013;4;CPC scale (best during trial);NA;functional/cognitive/neurological;n;NR;day 180;49;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
TTM 2013;5;modified Rankin Scale score;NA;functional/cognitive/neurological;n;NR;day 180;49;Included in scale;0,6;CCA;Descriptive plus p-value only;Chi-squared or Fisher
INSPIRATION 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30;42;Actual number of days;0;CCA;NA;Non-parametric
HOT-ICU 2021;1;DAWOLS;NA;days alive...;n;NR;day 90;42,6;Percentage of days out of the total number of days alive (not counting days where the patient was dead in either numerator or denominator);2,3;CCA;Descriptive plus p-value only;Non-parametric
HOT-ICU 2021;2;DAAOOH;NA;days alive...;n;NR;day 90;42,6;Percentage of days out of the total number of days alive (not counting days where the patient was dead in either numerator or denominator);2,3;CCA;Descriptive plus p-value only;Non-parametric
HOT-ICU 2021;3;EQ-5D-5L VAS;Survivors only;HRQoL;n;NR;1 year;48,9;Survivors only;7,7;CCA and MI and Best-worst/worst-best;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
HOT-ICU 2021;4;EQ-5D-5L VAS;All patients, dead = 0;HRQoL;n;NR;1 year;48,9;Dead = 0;7,7;CCA;Descriptive plus p-value only;Non-parametric
HOT-ICU 2021;5;EQ-5D-5L components;Survivors only;HRQoL;n;NR;1 year;48,9;Survivors only;6,8;CCA;Descriptive plus p-value only;Non-parametric
HOT-ICU 2021;6;EQ-5D-5L components;All patients, dead = worst category;HRQoL;n;NR;1 year;48,9;Dead = worst value;6,8;CCA;Descriptive plus p-value only;Non-parametric
HOT-ICU 2021;7;EQ-5D-5L index;Survivors only. Dutch, British, Danish (for all not covered by other value sets) value sets;HRQoL;n;NR;1 year;48,9;Survivors only;6,8;CCA;Descriptive plus p-value only;Non-parametric
HOT-ICU 2021;8;EQ-5D-5L index;All patients, dead = 0. Dutch, British, Danish (for all not covered by other value sets) value sets;HRQoL;n;NR;1 year;48,9;Dead = 0;6,8;CCA;Descriptive plus p-value only;Non-parametric
Schujmann 2019;1;Barthel Index;NA;functional/cognitive/neurological;y;NR;ICU discharge;13,3;Survivors only;2,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
Schujmann 2019;2;ICU mobility scale;NA;functional/cognitive/neurological;n;NR;ICU discharge;13,3;Survivors only;2,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
Schujmann 2019;3;Barthel Index >=85 (independent);NA;functional/cognitive/neurological;n;NR;ICU discharge;13,3;Survivors only;2,5;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Schujmann 2019;4;Barthel Index >=85 (independent);NA;functional/cognitive/neurological;n;NR;3 months after ICU discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Schujmann 2019;5;Hand grip strength;NA;functional/cognitive/neurological;n;NR;ICU discharge;13,3;Survivors only;2,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
Schujmann 2019;6;Sit and stand (repetitions);NA;functional/cognitive/neurological;n;NR;ICU discharge;13,3;Survivors only;2,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
Schujmann 2019;7;Timed up and go test;NA;functional/cognitive/neurological;n;NR;ICU discharge;13,3;Survivors only;2,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
Schujmann 2019;8;Stationary walk (repetitions);NA;functional/cognitive/neurological;n;NR;ICU discharge;13,3;Survivors only;2,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
Sehgal 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;14,4;NA;0;CCA;MD;Chi-squared or Fisher
SMART 2018;1;DAAOOICU;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0,6;CCA;OR;Non-parametric and POLR
SMART 2018;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0,6;CCA;OR;Non-parametric and POLR
SMART 2018;3;DAWOCS;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0,6;CCA;OR;Non-parametric and POLR
SMART 2018;4;DAWORRT;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0,6;CCA;OR;Non-parametric and POLR
VICTAS 2021;1;DAWO resp circ sup;NA;days alive...;y;NR;day 30;23;Dead = 0 days;0;LVCF;Median difference;Non-parametric and bootstrapping
VICTAS 2021;2;DAWO delirium/coma;NA;days alive...;n;NR;day 30;23;Dead = 0 days;0;LVCF;Median difference;Non-parametric and bootstrapping
VICTAS 2021;3;DAWORRT;NA;days alive...;n;NR;day 30;23;Dead = 0 days;0;LVCF;Median difference;Non-parametric and bootstrapping
VA/NIH 2008;1;Alive and at home off dialysis;"Home defined as ""previous living situation""";functional/cognitive/neurological;n;NR;day 60;52,6;Included in definition;0,3;CCA;OR;Logistic regression
VA/NIH 2008;2;DAWORRT;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
VA/NIH 2008;3;DAAOOH;NA;days alive...;n;NR;day 60;52,6;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
VA/NIH 2008;4;DAAOOICU;NA;days alive...;n;NR;day 60;52,6;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
SPICE III 2019;1;Institutional dependency;NA;functional/cognitive/neurological;n;NR;day 180;31,4;Survivors only;0,8;CCA;RD and OR;Logistic regression and GLM identity-binomial
SPICE III 2019;2;IQCODE short version (cognitive decline);NA;functional/cognitive/neurological;n;NR;day 180;31,4;Survivors only;14,2;CCA;MD;Linear regression/T-test/ANOVA/LMM
SPICE III 2019;3;EQ-5D-3L VAS;NA;HRQoL;n;NR;day 180;31,4;Survivors only;9,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
SPICE III 2019;4;DAWO delirium/coma;NA;days alive...;n;NR;day 28;NA;Actual number of days;0;CCA;Median difference;Quantile regression
SPICE III 2019;5;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;Median difference;Quantile regression
PReVENT 2018;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;33,5;Actual number of days;0,6;CCA;MD;Linear regression/T-test/ANOVA/LMM
COVINTOC 2021;1;Progression on Government of India Ministry of Health and Welfare COVID-19 ordinal scale for moderate to severe or severe to death;Levels: mild, moderate, severe, dead;ordinal/other;y;NR;day 14;9,5;Included in scale;0;CCA;RD;Chi-squared or Fisher and binomial proportion test/exact binomial CI
COVINTOC 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;14,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
COVINTOC 2021;3;DAAOOICU;NA;days alive...;n;NR;day 28;14,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
COVINTOC 2021;4;DAWO resp sup;NA;days alive...;n;NR;day 28;14,5;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Srisawat 2018;1;DAAOOICU;NA;days alive...;n;NR;day 28;54,2;NA;1,7;CCA;Descriptive plus p-value only;Non-parametric
Srisawat 2018;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;54,2;NA;1,7;CCA;Descriptive plus p-value only;Non-parametric
Srisawat 2018;3;DAWOCS;NA;days alive...;n;NR;day 28;54,2;NA;1,7;CCA;Descriptive plus p-value only;Non-parametric
VAPORISE 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0;CCA;Descriptive only;Descriptive only
DEXACET 2019;1;MoCA;NA;functional/cognitive/neurological;n;NR;hospital discharge;0;All included (no dead patients);0;CCA;Median difference;Non-parametric
DEXACET 2019;2;MoCA change from baseline;NA;functional/cognitive/neurological;n;NR;hospital discharge;0;All included (no dead patients);0;CCA;Median difference;Non-parametric
CoDEX 2020;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;58,9;Dead = 0 days;0;CCA;MD;GEE with ZOIB distribution
CoDEX 2020;2;Clinical status (6-level ordinal scale adapted from WHO ordinal scale);Levels: not hospitalized, hospitalized not requiring supplemental oxygen, hospitalized requiring supplemental oxygen, hospitalized requiring noninvasive ventilation or nasal high-flow oxygen therapy, hospitalized requiring invasive mechanical ventilation or ECMO, death;ordinal/other;n;NR;day 15;39,8;Included in scale;0;CCA;OR;POLR
CoDEX 2020;3;DAAOOICU;NA;days alive...;n;NR;day 28;58,9;Dead = 0 days;0;CCA;MD;GEE with ZOIB distribution
CoDEX 2020;4;Clinical status (6-level ordinal scale adapted from WHO ordinal scale) - cumulative;Levels: not hospitalized, hospitalized not requiring supplemental oxygen, hospitalized requiring supplemental oxygen, hospitalized requiring noninvasive ventilation or nasal high-flow oxygen therapy, hospitalized requiring invasive mechanical ventilation or ECMO, death;ordinal/other;n;NR;day 15;39,8;Included in scale;0;CCA;OR;Logistic regression and GLM identity-binomial
REVERSE-AKI 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 14 censored at ICU discharge;NA;Actual number of days;3;CCA;Median difference;NA
REVERSE-AKI 2021;2;DAWOCS;NA;days alive...;n;NR;day 14 censored at ICU discharge;NA;Actual number of days;3;CCA;Median difference;NA
REVERSE-AKI 2021;3;DAAOOICU;NA;days alive...;n;NR;day 14 censored at ICU discharge;NA;Actual number of days;3;CCA;Median difference;NA
REVERSE-AKI 2021;4;DAWORRT;NA;days alive...;n;NR;day 90;23,2;Actual number of days;4;CCA;Median difference;NA
REDUCE 2018;1;DAWO delirium/coma;NA;days alive...;n;NR;day 28;17,2;Actual number of days;15,8;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
REDUCE 2018;2;DAWO delirium;NA;days alive...;n;NR;day 28;17,2;Actual number of days;15,8;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
REDUCE 2018;3;DAWO coma;NA;days alive...;n;NR;day 28;17,2;Actual number of days;15,8;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
van Meenen 2018;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;31,5;Dead = 0 days;1,2;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
ADRENAL 2018;1;DAAOOICU;NA;days alive...;n;NR;day 90;28,3;Actual number of days;1,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
ADRENAL 2018;2;DAAOOH;NA;days alive...;n;NR;day 90;28,3;Actual number of days;1,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
ADRENAL 2018;3;DAWOMV/VFD;NA;days alive...;n;NR;day 90;28,3;Actual number of days;1,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
ADRENAL 2018;4;DAWORRT;NA;days alive...;n;NR;day 90;28,3;Actual number of days;1,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
ADRENAL 2018;5;EQ-5D-5L components;NA;HRQoL;n;Equal prioritisation;6 months;31,7;Survivors only;10,1;CCA;Descriptive plus p-value only;Chi-squared or Fisher
ADRENAL 2018;6;EQ-5D-5L index;Australian value set;HRQoL;n;NR;6 months;31,7;Survivors only;10,1;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
ADRENAL 2018;7;EQ-5D-5L VAS;NA;HRQoL;n;NR;6 months;31,7;Survivors only;10,1;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Villar 2020;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;NA;Dead = 0 days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
BACLOREA 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;23,5;Dead = 0 days;3,8;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
POPPI 2019;1;PSS-SR (PTSD);NA;HRQoL;y;NR;6 months;8,9;Survivors only;20,9;MI;MD;GEE with identity link
POPPI 2019;2;DAWO sedation;NA;days alive...;n;NR;day 30;NA;Dead = 0 days;0;CCA;MD;GEE with identity link
POPPI 2019;3;PSS-SR >18 (PTSD);NA;HRQoL;n;NR;6 months;8,9;Survivors only;0;CCA;OR;GEE with logit link
POPPI 2019;4;HADS domains;NA;HRQoL;n;Equal prioritisation;6 months;8,9;Survivors only;22,4;CCA;MD;GEE with identity link
POPPI 2019;5;EQ-5D-5L index;NA;HRQoL;n;NR;6 months;8,9;Survivors only;22,3;CCA;MD;GEE with identity link
Wang 2020;1;DAWOMV/VFD;NA;days alive...;n;NR;day 60;43,1;NA;0;CCA;Descriptive plus p-value only;Non-parametric
CIGMA 2018;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;25;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
CIGMA 2018;2;DAWOCS;NA;days alive...;n;NR;day 28;25;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
Wiberg 2016;1;CPC scale 3-5 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 30;30,5;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Wiberg 2016;2;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 30;30,5;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Wiberg 2016;3;CPC scale 3-5 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 90;32,2;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Wiberg 2016;4;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 90;32,2;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Wiberg 2016;5;CPC scale 3-5 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 180;33,1;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Wiberg 2016;6;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 180;33,1;Included in scale;0;CCA;Descriptive plus p-value only;Chi-squared or Fisher
REACTOR 2019;1;DAAOOICU;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
REACTOR 2019;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
REACTOR 2019;3;DAWOCS;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
RICH 2020;1;DAWORRT;NA;days alive...;n;NR;day 28;41,2;Actual number of days;1,5;CCA;Hodges-Lehmann estimate and HR;Non-parametric and Hodges-Lehmann estimator and time-to-event analysis
Doig 2015;1;RAND-36 general health;NA;HRQoL;n;NR;day 90;18,9;Survivors only;2,1;CCA;MD;Linear regression/T-test/ANOVA/LMM
Doig 2015;2;ECOG performance status;NA;functional/cognitive/neurological;n;NR;day 90;18,9;Survivors only;1,9;CCA;MD;Linear regression/T-test/ANOVA/LMM
Doig 2015;3;RAND-36 physical function;NA;functional/cognitive/neurological;n;NR;day 90;18,9;Survivors only;2,1;CCA;MD;Linear regression/T-test/ANOVA/LMM
ECMO-PT 2020;1;Discharge destination (4 levels);Levels: home, rehabilitation, other acute hospital, died in hospital;functional/cognitive/neurological;n;NR;hospital discharge;25;Included in definition;0;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;2;ICU mobility scale;NA;functional/cognitive/neurological;n;NR;hospital discharge;25;Survivors only;0;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;3;Katz Index;NA;functional/cognitive/neurological;n;NR;hospital discharge;25;Survivors only;0;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;4;Not in hospital;"Quote: ""Not in hospital (acute care, rehabilitation or nursing home)""";functional/cognitive/neurological;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;5;Lawton IADL;NA;functional/cognitive/neurological;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;6;Barthel Index;NA;functional/cognitive/neurological;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;7;MoCA Blind;NA;functional/cognitive/neurological;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;8;MoCA Blind;NA;functional/cognitive/neurological;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
ECMO-PT 2020;9;EQ-5D-5L VAS;NA;HRQoL;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
REMAP-CAP (antiviral domain) 2021;1;DAWO resp circ sup;NA;days alive...;y;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;2.4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (antiviral domain) 2021;2;DAWO resp sup;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;2.4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (antiviral domain) 2021;3;DAWOCS;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;2.4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (antiviral domain) 2021;4;WHO ordinal scale for COVID-19;NA;ordinal/other;n;NR;day 14;NA;Included in scale;NA;CCA;OR;Bayesian cumulative logistic regression model
Barrett 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;34;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
Barrett 2022;2;DAAOOICU;NA;days alive...;n;NR;day 28;34;Dead = 0 days;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
MUST-ARDS 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;30;Actual number of days;0;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;2;DAAOOICU;NA;days alive...;n;NR;day 28;30;Actual number of days;0;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;3;EQ-5D-3L index;NA;HRQoL;n;NR;day 28;30;Survivors only;20;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;4;EQ-5D-3L VAS;NA;HRQoL;n;NR;day 28;30;Survivors only;23,3;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;5;EQ-5D-3L index;NA;HRQoL;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;6;EQ-5D-3L VAS;NA;HRQoL;n;NR;day 90;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;7;EQ-5D-3L index;NA;HRQoL;n;NR;day 365;43,3;Survivors only;6,7;CCA;Descriptive only;Descriptive only
MUST-ARDS 2022;8;EQ-5D-3L VAS;NA;HRQoL;n;NR;day 365;43,3;Survivors only;6,7;CCA;Descriptive only;Descriptive only
Rosetti 2020;1;modified Rankin Scale score change;Change from prehospitalization to time of follow-up;functional/cognitive/neurological;n;NR;6 months;48,6;Included in scale;1,1;CCA;RR;Poisson/negative binomial regression and Chi-squared or Fisher
Rosetti 2020;2;CPC scale;NA;functional/cognitive/neurological;n;NR;6 months;48,6;Included in scale;1,1;CCA;RR;Poisson/negative binomial regression and Chi-squared or Fisher
REMAP-CAP (antiplatelet domain) 2022;1;DAWO resp circ sup;NA;days alive...;y;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;1,1;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (antiplatelet domain) 2022;2;DAWOCS;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;1,1;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (antiplatelet domain) 2022;3;DAWO resp sup;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;1,1;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (antiplatelet domain) 2022;4;WHO ordinal scale for COVID-19;NA;ordinal/other;n;NR;day 14;NA;Included in scale;0;CCA;OR;Bayesian cumulative logistic regression model
SETPOINT2 2022;1;modified Rankin Scale score 5-6 (poor outcome) ;NA;functional/cognitive/neurological;y;NR;6 months;32,2;Included in scale;3,4;MI;OR;Logistic regression
SETPOINT2 2022;2;modified Rankin Scale score;Categorical shift, all actual values;functional/cognitive/neurological;n;NR;6 months;32,2;Included in scale;3,4;MI;Descriptive only;Descriptive only
SETPOINT2 2022;3;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR;6 months;32,2;Included in scale;3,4;MI;OR;Logistic regression
SETPOINT2 2022;4;Discharge destination (4 levels);Home/rehabilitation center/long-term care facility/other (acute care hospital, palliative care facility, hospice, skilled nursing, step-down unit);functional/cognitive/neurological;n;NR;hospital discharge;NA;Survivors only;NA;CCA;Descriptive only;Descriptive only
SETPOINT2 2022;5;Location/support (5 levels);Home/hospital/rehabilitation center/long-term care facility/Other (monastery, assisted living, skilled nursing, nursing home);functional/cognitive/neurological;n;NR;6 months;32,2;Survivors only;0;CCA;Descriptive only;Descriptive only
Campos 2022;1;Functional Status Score for the ICU;NA;functional/cognitive/neurological;y;NR;ICU discharge;39,3;Survivors only;22,1;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;2;Medical Research Council muscle strength;NA;functional/cognitive/neurological;n;NR (individual categories/domains secondarily reported but not analysed);ICU discharge;39,3;Survivors only;27,9;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;3;Medical Research Council muscle strength, lower limbs;NA;functional/cognitive/neurological;n;NR (individual categories/domains secondarily reported but not analysed);ICU discharge;39,3;Survivors only;27,9;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;4;Medical Research Council muscle strength <48 (ICU-acquired weakness);NA;functional/cognitive/neurological;n;NR;ICU discharge;39,3;Survivors only;27,9;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Campos 2022;5;Physical Function in the ICU Test;NA;functional/cognitive/neurological;n;NR;ICU discharge;39,3;Survivors only;27,9;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;6;Barthel Index;NA;functional/cognitive/neurological;n;NR;ICU discharge;39,3;Survivors only;1,6;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;7;EQ-5D-3L index;NA;HRQoL;n;NR;ICU discharge;39,3;Survivors only;25,4;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;8;EQ-5D-3L VAS;NA;HRQoL;n;NR;ICU discharge;39,3;Survivors only;25,4;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;9;Functional Status Score for the ICU;NA;functional/cognitive/neurological;n;NR;hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;10;Medical Research Council muscle strength;NA;functional/cognitive/neurological;n;NR (individual categories/domains secondarily reported but not analysed);hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;11;Medical Research Council muscle strength, lower limbs;NA;functional/cognitive/neurological;n;NR (individual categories/domains secondarily reported but not analysed);hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;12;Physical Function in the ICU Test;NA;functional/cognitive/neurological;n;NR;hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;13;Barthel Index;NA;functional/cognitive/neurological;n;NR;hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;14;EQ-5D-3L index;NA;HRQoL;n;NR;hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
Campos 2022;15;EQ-5D-3L VAS;NA;HRQoL;n;NR;hospital discharge;NA;Survivors only;NA;CCA;Descriptive plus p-value only;Non-parametric
ANALGESIC 2021;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28 censored at hospital discharge;13,4;Dead = 0 days;0;CCA;Median difference and OR;Quantile regression and bootstrapping and time-to-event analysis and GAM with ZIB distribution and POLR and non-parametric
ANALGESIC 2021;2;DAAOOICU;NA;days alive...;n;NR;day 28;13,4;Dead = 0 days;0;CCA;Median difference;Quantile regression and bootstrapping
ANALGESIC 2021;3;DAAOOH;NA;days alive...;n;NR;day 28;13,4;Dead = 0 days;0;CCA;Median difference;Quantile regression and bootstrapping
FLORALI-IM 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;35,8;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
FLORALI-IM 2022;2;DAWOHFNOorNIV;NA;days alive...;n;NR;day 28;35,8;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
BREATHE 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 29;NA;Dead = 0 days;2,7;MI;Descriptive plus p-value only;GLM(M) with logit link plus G-computation and bootstrapping
TTM2 2021;1;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR (individual categories/domains secondarily reported but not analysed);6 months;49,2;Included in scale;6,2;CCA and Best-worst/worst-best;RR;GLM(M) with logit link plus G-computation and bootstrapping
TTM2 2021;2;Poor outcome;Based on mRS 4-6 for those available, but just dichotomised for the rest;functional/cognitive/neurological;n;NR;6 months;49,2;Included in scale;1,7;CCA and Best-worst/worst-best;;
TTM2 2021;3;DAAOOH;NA;days alive...;n;NR;6 months;49,2;Actual number of days;0,6;CCA;Descriptive only;Descriptive only
TTM2 2021;4;EQ-5D-5L VAS;NA;HRQoL;n;NR;6 months;49,2;Dead = 0;7,5;CCA;Descriptive only;Descriptive only
TTM2 2021;5;EQ-5D-5L VAS;Survivors only;HRQoL;n;NR;6 months;49,2;Survivors only;7,5;CCA;MD;Linear regression/T-test/ANOVA/LMM
COV-AID 2021;1;Time to clinical improvement (6 level ordinal scale);">= 2 point increase on a 6-category ordinal scale compared with worst stage at randomisation, or discharge from hospital alive. Levels: death / hospitalised, on invasive mechanical ventilation or extracorporeal
membrane oxygenation /hospitalised, on non-invasive ventilation or high-flow oxygen devices / hospitalised, requiring supplemental oxygen / hospitalised, not requiring supplemental oxygen / not hospitalised.";ordinal/other;y;NR;hospital discharge;16,1;Included in scale;0;CCA;HR;Time-to-event analysis
COV-AID 2021;2;DAWO resp sup;Oxygen-supplementation free days;days alive...;n;NR;day 28;NA;NA;1,5;CCA;IRR/expected count ratio;Poisson/negative binomial regression
COV-AID 2021;3;DAWOMV/VFD;;days alive...;n;NR;day 28;NA;NA;1,5;CCA;IRR/expected count ratio;Poisson/negative binomial regression
Drewry 2022;1;DAAOOH;NA;days alive...;n;NR;day 28;30,4;NA;0;CCA;NA;Non-parametric
Drewry 2022;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;30,4;NA;0;CCA;NA;Non-parametric
BOUGIE 2021;1;DAAOOICU;NA;days alive...;n;NR;day 28 censored at hospital discharge;30,5;Dead = 0 days;0;CCA;Median difference;Bootstrapping
BOUGIE 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28 censored at hospital discharge;30,5;Dead = 0 days;0;CCA;Median difference;Bootstrapping
COV-BARRIER 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;48,5;NA;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
COV-BARRIER 2022;2;Clinical improvement (8-level ordinal scale);National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 4;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;3;Clinical improvement (8-level ordinal scale);National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 7;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;4;Clinical improvement (8-level ordinal scale);National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 10;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;5;Clinical improvement (8-level ordinal scale);National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 14;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;6;Clinical improvement (8-level ordinal scale);National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 21;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;7;Clinical improvement (8-level ordinal scale);National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 28;48,5;Included in scale;4;CCA;OR;POLR
COV-BARRIER 2022;8;Clinical improvement (>=1 point on 8-level ordinal scale) or live discharge from hospital;National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 4;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;9;Clinical improvement (>=1 point on 8-level ordinal scale) or live discharge from hospital;National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 7;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;10;Clinical improvement (>=1 point on 8-level ordinal scale) or live discharge from hospital;National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 10;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;11;Clinical improvement (>=1 point on 8-level ordinal scale) or live discharge from hospital;National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 14;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;12;Clinical improvement (>=1 point on 8-level ordinal scale) or live discharge from hospital;National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 21;NA;Included in scale;NA;CCA;OR;POLR
COV-BARRIER 2022;13;Clinical improvement (>=1 point on 8-level ordinal scale) or live discharge from hospital;National Institute of Allergy and Infectious Disease (NIAID) ordinal scale score - 8 levels. Levels: not hospitalized, no limitation on activities / not hospitalized, limitations on activities and/or requiring home O2 / hospitalized, no supplemental O2 - no longer requires ongoing medical care / hospitalized, no supplemental O2 - requiring onging medical care / hospitalized, requiring supplemental O2 / hospitalized, on non-invasive ventilation or high-flow oxygen devices / hospitalized, on invasive mechanical ventilation or ECMO / death.;ordinal/other;n;NR;day 28;48,5;Included in scale;4;CCA;OR;POLR
REMAP-CAP (immunoglobulin domain) 2021;1;DAWO resp circ sup;NA;days alive...;y;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;0,4;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (immunoglobulin domain) 2021;2;DAWO resp sup;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;0,5;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (immunoglobulin domain) 2021;3;DAWOCS;NA;days alive...;n;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;0,5;CCA;OR;Bayesian cumulative logistic regression model
REMAP-CAP (immunoglobulin domain) 2021;4;WHO ordinal scale for COVID-19;NA;ordinal/other;n;NR;day 14;NA;Included in scale;0,4;CCA;OR;Bayesian cumulative logistic regression model
PLUS 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 90;21,9;Actual number of days;1,1;CCA with logical imputation of intermittent missing repeated values;MD;Linear regression/T-test/ANOVA/LMM
PLUS 2022;2;DAWOCS;NA;days alive...;n;NR;day 90;21,9;Actual number of days;1,1;CCA with logical imputation of intermittent missing repeated values;MD;Linear regression/T-test/ANOVA/LMM
PLUS 2022;3;DAAOOICU;NA;days alive...;n;NR;day 90;21,9;Actual number of days;1,1;CCA with logical imputation of intermittent missing repeated values;MD;Linear regression/T-test/ANOVA/LMM
PLUS 2022;4;DAAOOH;NA;days alive...;n;NR;day 90;21,9;Actual number of days;1,1;CCA with logical imputation of intermittent missing repeated values;MD;Linear regression/T-test/ANOVA/LMM
ObiWEAN 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;NA;NA;CCA;MD;Bootstrapping
COMPACT-2 2021;1;DAAOOICU;NA;days alive...;n;NR;day 30;NA;NA;NA;CCA;Descriptive plus p-value only;Non-parametric
Gelissen 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 14;NA;NA;0;CCA;Hodges-Lehmann estimate;Hodges-Lehmann estimator
REMAP-CAP, ACTIV-4a, ATTACC (anticoagulation) 2021;1;DAWO resp circ sup;NA;days alive...;y;NR;day 21 (assumed alive and without life support after hospital discharge);NA;Dead = worst value, ordinal;0,5;CCA;OR;Bayesian cumulative logistic regression model
TARGET 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28 censored at ICU discharge;23,7;NA;0,4;CCA;Descriptive plus p-value only;Non-parametric
TARGET 2022;2;DAWOCS;NA;days alive...;n;NR;day 14 censored at ICU discharge;NA;NA;0,4;CCA;Descriptive plus p-value only;Non-parametric
TARGET 2022;3;DAWORRT ;NA;days alive...;n;NR;day 28 censored at ICU discharge;23,7;NA;0,4;CCA;Descriptive plus p-value only;Non-parametric
REDOXS 2013;1;Time to ICU separation;Dead = considered never separated;days alive...;n;NR;6 months;40,5;Dead = worst value (time to liberation outcome);0;CCA;Descriptive plus p-value only;Time-to-event analysis
REDOXS 2013;2;Time to hospital discharge;Dead = considered never discharged;days alive...;n;NR;6 months;40,5;Dead = worst value (time to liberation outcome);0;CCA;Descriptive plus p-value only;Time-to-event analysis
REDOXS 2013;3;Time to ventilator separation;Dead = considered never separated;days alive...;n;NR;6 months;40,5;Dead = worst value (time to liberation outcome);0;CCA;Descriptive plus p-value only;Time-to-event analysis
He 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;23,9;Dead = 0 days;0;CCA;Descriptive plus p-value only;Non-parametric
Ibarra-Estrada 2022;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;68,9;Dead = 0 days;1,1;CCA;Descriptive plus p-value only;Non-parametric
COMBAT-COVID 2022;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;32,5;NA;0;CCA;Median difference;Non-parametric and bootstrapping
COMBAT-COVID 2022;2;DAWOMV/VFD;NA;days alive...;n;NR;day 90;40;NA;0;CCA;Median difference;Non-parametric and bootstrapping
COMBAT-COVID 2022;3;DAWOCS;NA;days alive...;n;NR;day 28;32,5;NA;0;CCA;Median difference;Non-parametric and bootstrapping
COMBAT-COVID 2022;4;DAWOCS;NA;days alive...;n;NR;day 90;40;NA;0;CCA;Median difference;Non-parametric and bootstrapping
COMBAT-COVID 2022;5;DAWORRT;NA;days alive...;n;NR;day 28;32,5;NA;0;CCA;Median difference;Non-parametric and bootstrapping
COMBAT-COVID 2022;6;DAWORRT;NA;days alive...;n;NR;day 90;40;NA;0;CCA;Median difference;Non-parametric and bootstrapping
ACCOST-HH 2022;1;DAWOCS;NA;days alive...;y;NR;day 30;40;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM
ACCOST-HH 2022;2;6-minute walking test;NA;functional/cognitive/neurological;n;NR;day 30;40;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
ACCOST-HH 2022;3;6-minute walking test;NA;functional/cognitive/neurological;n;NR;day 90;45,3;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
NEED 2022;1;DAAOOICU;NA;days alive...;n;NR;day 28;14,7;Dead = 0 days;3,6;CCA;MD;Linear regression/T-test/ANOVA/LMM
ISOCRATE 2021;1;CPC scale 1-2 (alive with good neurological outcome);NA;functional/cognitive/neurological;n;NR;day 90;40;Included in scale;0;CCA;NA;NA
AdrenOSS-2 2021;1;Delta Sepsis Support Index;NA;days alive...;n;NR (individual components reported secondarily) ;day 14;18,9;Actual point score (no penalisation of death);1,7;CCA;MD and Hodges-Lehmann estimate;Linear regression/T-test/ANOVA/LMM and non-parametric and Hodges-Lehmann estimator
AdrenOSS-2 2021;2;Delta Sepsis Support Index;Death penalised as bad outcome in all support domains;days alive...;n;NR (individual components reported secondarily) ;day 14;18,9;Worst possible point score on days where the patient was dead;1,7;CCA;MD and Hodges-Lehmann estimate;Linear regression/T-test/ANOVA/LMM and non-parametric and Hodges-Lehmann estimator
AdrenOSS-2 2021;3;Delta Sepsis Support Index;NA;days alive...;n;NR (individual components reported secondarily) ;day 28;25,6;Actual point score (no penalisation of death);1,7;CCA;MD and Hodges-Lehmann estimate;Linear regression/T-test/ANOVA/LMM and non-parametric and Hodges-Lehmann estimator
AdrenOSS-2 2021;4;Delta Sepsis Support Index;Death penalised as bad outcome in all support domains;days alive...;n;NR (individual components reported secondarily) ;day 28;25,6;Worst possible point score on days where the patient was dead;1,7;CCA;MD and Hodges-Lehmann estimate;Linear regression/T-test/ANOVA/LMM and non-parametric and Hodges-Lehmann estimator
AdrenOSS-2 2021;5;EQ-5D VAS (unclear if 3L or 5L);NA;HRQoL;n;NR;ICU discharge;NA;Survivors only;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
AdrenOSS-2 2021;6;EQ-5D VAS (unclear if 3L or 5L);NA;HRQoL;n;NR;day 90;34,2;Survivors only;10,3;CCA;MD;Linear regression/T-test/ANOVA/LMM
AdrenOSS-2 2021;7;EQ-5D VAS (unclear if 3L or 5L);Difference from ICU discharge to day 90;HRQoL;n;NR;day 90;34,2;Survivors only;23,3;CCA;MD;Linear regression/T-test/ANOVA/LMM
CAPITAL CHILL 2021;1;Mortality or poor neurological outcome;Poor neurological outcome defined as a Disability Rating Scale >5 or modified Rankin Scale score of 4-6;functional/cognitive/neurological;y;NR;day 180;42,8;Included in definition;0,3;MI;RD and RR and OR;Logistic regression and Chi-squared or Fisher
CAPITAL CHILL 2021;2;Disability Rating Scale >5;NA;functional/cognitive/neurological;n;NR;day 180;42,8;Survivors only;0,3;MI;RD and RR;Chi-squared or Fisher
CAPITAL CHILL 2021;3;Disability Rating Scale (categorised);Categorised as: 0-5 / 6-10 / 11-15 / 16-20 / 21-29;functional/cognitive/neurological;n;NR;day 180;42,8;Survivors only;0,3;MI;Descriptive plus p-value only;Chi-squared or Fisher
CAPITAL CHILL 2021;4;modified Rankin Scale score 4-6 (poor outcome);NA;functional/cognitive/neurological;n;NR;day 180;42,8;Included in scale;0,3;MI;RD and RR;Chi-squared or Fisher
CAPITAL CHILL 2021;5;modified Rankin Scale score;NA;functional/cognitive/neurological;n;NR;day 180;42,8;Included in scale;0,3;MI;RD and RR;Chi-squared or Fisher
HYPO-ECMO 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30;46,4;Actual number of days;0,6;MI;MD and OR;GEE with identity link and POLR
HYPO-ECMO 2022;2;DAWOMV/VFD;NA;days alive...;n;NR;day 60;51,8;Actual number of days;0,6;MI;MD and OR;GEE with identity link and POLR
HYPO-ECMO 2022;3;DAWOMV/VFD;NA;days alive...;n;NR;day 180;55,1;Actual number of days;0,6;MI;MD and OR;GEE with identity link and POLR
HYPO-ECMO 2022;4;DAWORRT;NA;days alive...;n;NR;day 30;46,4;Actual number of days;0,6;MI;MD and OR;GEE with identity link and POLR
HYPO-ECMO 2022;5;DAWORRT;NA;days alive...;n;NR;day 60;51,8;Actual number of days;0,6;MI;MD and OR;GEE with identity link and POLR
HYPO-ECMO 2022;6;DAWORRT;NA;days alive...;n;NR;day 180;55,1;Actual number of days;0,6;MI;MD and OR;GEE with identity link and POLR
ICAR 2022;1;DAWOMV/VFD;NA;days alive...;y;NR;day 28;30,1;Dead = 0 days;1,4;Single imputation - worst case imputation;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
ICAR 2022;2;WHO ordinal scale for COVID-19 (only some levels);WHO ordinal scale for COVID-19, but lowest levels (1: uninfected, no viral RNA detected and 2: asymptomatic, viral RNA detected) and highest level (10: dead) not included;ordinal/other;n;NR;day 28;30,1;Survivors only;4,8;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
ICAR 2022;3;WHO ordinal scale for COVID-19 (only some levels);WHO ordinal scale for COVID-19, but lowest levels (1: uninfected, no viral RNA detected and 2: asymptomatic, viral RNA detected) and highest level (10: dead) not included;ordinal/other;n;NR;day 90;40,4;Survivors only;2,7;CCA;Hodges-Lehmann estimate;Non-parametric and Hodges-Lehmann estimator
REST 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;36,9;Dead = 0 days;0,5;CCA;MD;Linear regression/T-test/ANOVA/LMM and non-parametric
Sedaconda 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30 after end of study sedation (48h) or extubation;21,6;NA;NA;CCA;MD;Linear regression/T-test/ANOVA/LMM
Sedaconda 2021;2;DAAOOICU;NA;days alive...;n;NR;day 30 after end of study sedation (48h) or extubation;21,6;NA;NA;Imputation - details unclear;MD;Linear regression/T-test/ANOVA/LMM
Sedaconda 2021;3;DAWO delirium;NA;days alive...;n;NR;day 7 after end of study sedation (48h) or extubation;7,5;Actual number of days;NA;Imputation - details unclear;Descriptive plus p-value only;NA
Sedaconda 2021;4;DAWO coma;NA;days alive...;n;NR;day 7 after end of study sedation (48h) or extubation;7,5;Actual number of days;NA;Imputation - details unclear;Descriptive plus p-value only;NA
STROMA-CoV-2 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;22;NA;8,9;CCA;Median difference;Non-parametric
COVID STEROID 2 2021;1;DAWOLS;NA;days alive...;y;NR (individual categories/domains secondarily reported but not analysed);day 28;29,7;Actual number of days;0;CCA and Best-worst/worst-best;MD and median difference and IRR/expected count ratio;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping and quantile regression and hurdle-negative binomial regression
COVID STEROID 2 2021;2;DAWOLS;NA;days alive...;n;NR (individual categories/domains secondarily reported but not analysed);day 90;34,8;Actual number of days;0,4;CCA;MD and median difference and IRR/expected count ratio;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping and quantile regression and hurdle-negative binomial regression
COVID STEROID 2 2021;3;DAAOOH;NA;days alive...;n;NR;day 90;34,8;Actual number of days;0,3;CCA;MD and median difference and IRR/expected count ratio;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping and quantile regression and hurdle-negative binomial regression
COVID STEROID 2 2021;4;DAWOLS;Sensitivity analysis, dead = 0;days alive...;n;NR (individual categories/domains secondarily reported but not analysed);day 28;29,7;Dead = 0 days;0;CCA;MD and median difference and IRR/expected count ratio;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping and quantile regression and hurdle-negative binomial regression
COVID STEROID 2 2021;5;DAWOLS;Sensitivity analysis, dead = 0;days alive...;n;NR;day 90;34,8;Dead = 0 days;0,4;CCA;MD and IRR/expected count ratio;Hurdle-negative binomial regression and linear regression/T-test/ANOVA/LMM and bootstrapping
COVID STEROID 2 2021;6;DAAOOH;Sensitivity analysis, dead = 0;days alive...;n;NR;day 90;34,8;Dead = 0 days;0,3;CCA;MD and IRR/expected count ratio;Hurdle-negative binomial regression and linear regression/T-test/ANOVA/LMM and bootstrapping
COVID STEROID 2 2021;7;EQ-5D-5L index;Danish, Indian, Swedish, German value sets (last one used for Switzerland);HRQoL;n;NR (individual categories/domains secondarily reported but not analysed);day 180;36,1;Dead = 0;3,2;MI and Best-worst/worst-best and CCA;MD and median difference;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping and quantile regression
COVID STEROID 2 2021;8;EQ-5D-5L VAS;NA;HRQoL;n;NR;day 180;36,1;Dead = 0;3,2;MI and Best-worst/worst-best and CCA;MD and median difference;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping and quantile regression
COVID STEROID 2 2021;9;EQ-5D-5L index;Sensitivity analysis, Danish value set for all patients;HRQoL;n;NR;day 180;36,1;Dead = 0;3,2;MI;MD;Linear regression/T-test/ANOVA/LMM and bootstrapping
COVID STEROID 2 2021;10;EQ-5D-5L index;Sensitivity analysis, survivors only;HRQoL;n;NR (individual categories/domains secondarily reported but not analysed);day 180;36,1;Survivors only;3,2;MI;MD;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping
COVID STEROID 2 2021;11;EQ-5D-5L VAS;Sensitivity analysis, survivors only;HRQoL;n;NR (individual categories/domains secondarily reported but not analysed);day 180;36,1;Survivors only;3,2;MI;MD;Kryger-Jensen/Lange test and Linear regression/T-test/ANOVA/LMM and bootstrapping
HiFLo-COVID 2021;1;Time to clinical recovery (7-level ordinal scale);"Time until reduction of >=2 point on 7-level ordinal scale. Levels: discharged from the hospital, resuming complete daily-life activities / discharged from the hospital but with limitation of activities, home oxygen requirement, or both / hospitalized in a general ward (not intensive care unit), not requiring supplemental oxygen, and no longer requiring ongoing medical care (used if hospitalization was extended for infection
control reasons) / hospitalized in a general ward (not intensive care unit), requiring supplemental oxygen or requiring ongoing medical care / hospitalized in the intensive care unit, requiring any supplemental oxygen / hospitalized in the intensive care unit, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation / death.";ordinal/other;y;NR;day 28;12,1;Included in scale;6,1;CCA;HR and RD;Time-to-event analysis and bootstrapping
HiFLo-COVID 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;12,1;NA;6,1;CCA;Median difference and OR;Bootstrapping and POLR
HiFLo-COVID 2021;3;DAWORRT;NA;days alive...;n;NR;day 28;12,1;NA;6,1;CCA;Median difference and OR;Bootstrapping and POLR
HiFLo-COVID 2021;4;Clinical status (7-level ordinal scale);"7-level ordinal scale. Levels: discharged from the hospital, resuming complete daily-life activities / discharged from the hospital but with limitation of activities, home oxygen requirement, or both / hospitalized in a general ward (not intensive care unit), not requiring supplemental oxygen, and no longer requiring ongoing medical care (used if hospitalization was extended for infection
control reasons) / hospitalized in a general ward (not intensive care unit), requiring supplemental oxygen or requiring ongoing medical care / hospitalized in the intensive care unit, requiring any supplemental oxygen / hospitalized in the intensive care unit, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation / death.";ordinal/other;n;NR;day 28;12,1;Included in scale;6,1;CCA;OR;POLR
UNDERPIN-ICU 2021;1;DAWO delirium/coma;NA;days alive...;y;NR;day 28;32,6;Actual number of days;0;CCA;MD;Linear regression/T-test/ANOVA/LMM and bootstrapping
TELSTAR 2022;1;CPC scale 1-2 (alive with good neurological outcome);NA;functional/cognitive/neurological;y;NR;3 months;80,8;Included in scale;0;CCA;RD;Simple calculation
TELSTAR 2022;2;CPC scale;NA;functional/cognitive/neurological;n;NR;3 months;80,8;Included in scale;0;CCA;OR;POLR
TELSTAR 2022;3;CPC scale 2-5;NA;functional/cognitive/neurological;n;NR;3 months;80,8;Included in scale;0;CCA;RD;Simple calculation
TELSTAR 2022;4;CPC scale 4-5;NA;functional/cognitive/neurological;n;NR;3 months;80,8;Included in scale;0;CCA;RD;Simple calculation
RADAR-2 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;18,4;NA;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
RADAR-2 2022;2;DAAOOICU;NA;days alive...;n;NR;day 28;18,4;NA;0;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
RADAR-2 2022;3;MoCA Blind  ;NA;functional/cognitive/neurological;n;NR;day 180;26,1;Survivors only;52;CCA;Descriptive plus p-value only;Chi-squared or Fisher
RADAR-2 2022;4;EQ-5D-5L index;NA;HRQoL;n;NR;day 180;26,1;Survivors only;52;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
RADAR-2 2022;5;EQ-5D-5L VAS;NA;HRQoL;n;NR;day 180;26,1;Survivors only;52;CCA;Descriptive plus p-value only;Linear regression/T-test/ANOVA/LMM
RADAR-2 2022;6;HADS anxiety/depression (>=11);NA;HRQoL;n;Equal prioritisation;day 180;26,1;Survivors only;52;CCA;Descriptive plus p-value only;Chi-squared or Fisher
RADAR-2 2022;7;PTSD - IES-R score >=33;NA;HRQoL;n;NR;day 180;26,1;Survivors only;52;CCA;Descriptive plus p-value only;Chi-squared or Fisher
Pro-MEDIC 2022;1;DAWO delirium;NA;days alive...;n;NR;day 14 censored at ICU discharge;NA;Percentage of days out of the total number of days with possible condition (not counting days where the patient was dead or discharged from the ICU in either numerator or denominator);0,1;CCA;Descriptive plus p-value only;Non-parametric
Pro-MEDIC 2022;2;DAWO delirium/coma;NA;days alive...;n;NR;day 14 censored at ICU discharge;NA;Percentage of days out of the total number of days with possible condition (not counting days where the patient was dead or discharged from the ICU in either numerator or denominator);0,1;CCA;Descriptive plus p-value only;Non-parametric
ACIdoSIS 2021;1;DAWOCS;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;Descriptive plus p-value only;Non-parametric
ACIdoSIS 2021;2;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;NA;0;CCA;Descriptive plus p-value only;Non-parametric
ACIdoSIS 2021;3;DAWORRT;Continuous RRT-free days;days alive...;n;NR;day 28;NA;NA;0;CCA;Descriptive plus p-value only;Non-parametric
BaSICs 2021;1;DAWOMV/VFD;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0,2;CCA;MD;Beta-binomial regression (including Bayesian beta-binomial regression)
BaSICs 2021;2;DAWORRT;NA;days alive...;n;NR;day 28;NA;Dead = 0 days;0,7;Partial single imputation - best case/normal imputation;MD;Beta-binomial regression (including Bayesian beta-binomial regression)
INSPIRATION-S 2022;1;DAWOMV/VFD;NA;days alive...;n;NR;day 30;33,4;Actual number of days;0;CCA;Descriptive plus p-value only;Non-parametric